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ABSTRACT 
Sickle cell anemia, caused by a point mutation that affects the HBB gene, is one of the most 
common human genetic disorders world-wide and has a high morbidity and mortality. A single 
FDA approved drug, hydroxyurea, is available for its ability to induce fetal hemoglobin 
expression, a major modulator of disease severity. Not every patient responds to treatment and 
additional HbF-inducing drugs are needed. In this thesis, I outline an induced pluripotent stem 
cell-based approach to the study of sickle cell disease (SCD). In the lab, we are currently building 
a library of SCD-induced pluripotent stem cell (iPSC) lines from a cohort of SCD patients with 
different genetic backgrounds and fetal hemoglobin levels. Utilizing a directed-differentiation 
approach, iPSC can give rise to hematopoietic progenitors that are similar to megakaryocyte-
erythroid progenitors and can be further specified to become cells of either lineage. I examined 
the hypothesis that an iPSC-based system would be capable of producing fully functional 
erythroid cells and also recapitulate the variation in fetal hemoglobin levels seen in SCD patients. 
Directed-differentiation of iPSCs produced erythroid-lineage cells that were responsive to oxygen 
levels and erythropoietin, and were capable of further maturation and increased hemoglobin 
production. A humanized mouse model demonstrated the ability of these cells to localize to the 
bone marrow, contribute to the peripheral blood, and survive in vivo for over two weeks. The 
maturation capability of SCD-specific iPSC-derived erythroid lineage cells was correlated with 
   viii 
hemoglobin expression and compared to control cells. Characterization of in vitro and in vivo 
differences between control and SCD-specific iPSC-derived erythroid-lineage cells demonstrated 
variation amongst individuals, similar to the variation seen in patients. Both of these patient-
specific iPSC-based in vitro and in vivo models allow for the examination of the effect of genetic 
variability on fetal hemoglobin expression and also for the modeling of patient-specific responses 
to drug treatment. This information will facilitate better clinical treatment of the disease. 
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CHAPTER 1: 
GENERAL INTRODUCTION 
 
The study of hematopoiesis 
Hematopoiesis: a brief description of the blood system. 
A hierarchal process, hematopoiesis involves a series of cell fate decisions that lead to the 
production of eight distinct blood cell types, all with unique roles (Figure 1.1). In the adult, the 
hematopoietic stem cell (HSC) remains quiescent in the bone marrow until signaled to divide, 
allowing it to produce all blood cell types through a series of differentiation steps and progenitors 
without stem cell exhaustion1. Two major hematopoietic progenitors derived from the HSC, the 
common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP), will undergo 
both propagation and differentiation to produce myeloid2 and lymphoid3 blood cells.  
Both the CMP and the CLP are the source of immune cells. The CLP gives rise to the 
lymphoid compartment consisting of B and T lymphocytes3. B cell lymphocytes are important for 
adaptive immunity by recognizing foreign antigens and stimulating antibody production for 
recognition and destruction of foreign objects4. T cell lymphocytes direct the immune system’s 
defense in two manners: through the regulation of the immune response and the actual attack of 
infected cells4. The CMP is responsible for the production of granulocytes and monocytes (the 
most mature form known as macrophages) through the derivation of the granulocyte macrophage 
progenitor (GMP)2. Granulocytes, also known as white blood cells, are identified by the staining 
properties of their cytoplasm and their unique role in identification of microorganisms in the 
body. Neutrophils recognize bacteria; eosinophils specialize in parasitic recognition; and 
basophils release histamine to stimulate inflammatory responses5. Imperative to both adaptive and 
innate immunity, macrophages are accountable for the engulfment and digestion of cellular debris  
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Figure 1.1. Schematic of hematopoiesis. Hematopoiesis is responsible for the derivation of 8 
distinct cell types that make up the blood system through the hematopoietic stem cell (HSC) and 
progenitors such as the common lymphoid progenitor (CLP), the common myeloid progenitor 
(CMP), the granulocyte macrophage progenitor (GMP) and the megakaryocyte erythroid 
progenitor (MEP). Adapted from http://students.uccaribe.net/forums/topic/hematopoiesis-
histology-image  
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and pathogens5. While cells produced by the CLP and CMP are responsible for the immune 
system, the CMP is also a progenitor for other essential blood cells. 
Thrombocytes and erythrocytes are created from the megakaryocyte erythroid progenitor 
(MEP), another progenitor derived from the CMP2. These cells transport oxygen and create clots 
at the site of injury. Erythrocytes, commonly called red blood cells (RBC), utilize hemoglobin to 
uptake oxygen in the lungs and exchange it for carbon dioxide in the peripheral tissues5. 
Thrombocytes, also known as platelets, are cell fragments that have been derived from and 
detached from megakaryocytes. They adhere to endothelial cells in blood vessels at the site of 
injury to form clots5. 
In Homo sapiens, two separate waves of hematopoiesis occur to produce all the cells in 
the blood system, primitive and definitive. While both arise during embryogenesis, only 
definitive persists into adulthood. Primitive hematopoiesis is responsible for the production of 
cells to carry oxygen to the developing embryo. Definitive hematopoiesis is required for the more 
complex hematopoietic system developed in the embryo and continued throughout adult life. 
 
 
 
Figure 1.2. The cell source for hematopoiesis changes concurrently with the site of 
hematopoiesis. As illustrated in mice, as the site of hematopoiesis changes so does the source 
from which all blood cells are derived. From Orkin and Zon6. 
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Primitive Hematopoiesis: the earliest phase of hematopoiesis 
Hematopoiesis can be classified by the location in which it is occurring, and the source of the 
hematopoietic lineages. In mammals, the location of hematopoiesis transitions multiple times 
during development. Initiated in the yolk sac, it is transiently found in the aorta-gonad 
mesonephros (AGM) region, before residing in the fetal liver and ultimately the bone marrow6. 
Along with the transition in locations, is the transition in the source of hematopoietic lineage 
cells. Primitive hematopoiesis, the initial wave of hematopoiesis in the yolk sac is essential for 
the early production of RBCs7. This wave of hematopoiesis is termed primitive due to the 
hallmark expression of embryonic hemoglobin and the belief that the resulting RBCs are not 
produced from a hematopoietic stem cell, but the hemangioblast (Figure 1.2). The 
hemangioblast, while short lived, is a multipotent progenitor responsible for the production of 
hematopoietic and endothelial cells during early development8–10. Not long after production in the 
yolk sac, the site of hematopoiesis transitions to the AGM and fetal liver in which the first few 
HSCs are found and definitive hematopoiesis can begin11. 
 
Definitive Hematopoiesis: a HSC mediated production of blood cells 
The period when cells in the blood system are produced from the HSC is classified as definitive 
hematopoiesis. Unlike primitive hematopoiesis, definitive will persist throughout adulthood, 
despite changes in location. It is unclear whether the HSCs found in the AGM and fetal liver are 
responsible for colonizing the bone marrow or if a separate wave of HSCs is responsible6,12 
(Figure 1.2 & 1.3). Definitive hematopoiesis can be found in four main locations during 
embryonic development: AGM, placenta, fetal liver, and the bone marrow13. Hemoglobin 
expression changes during embryonic development with fetal hemoglobin expressed early and 
transitioning to adult globin at the end of gestation. 
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Figure 1.3. Schematic of the development of the human hematopoietic system. The yolk sac 
is the site of embryonic hematopoiesis, which then proceeds to the fetal liver after the onset of 
circulation. A second colonization occurs leading to the site of hematopoiesis arriving in the bone 
marrow at ~10.5 weeks and the thymus at 9-10.5 weeks. From Jagannathan-Bogdan and Zon14. 
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The study of erythropoiesis 
Erythropoiesis: A brief overview of the process of erythropoiesis 
Erythropoiesis refers to the process of production of RBCs, which in humans, occurs in red bone 
marrow. Erythropoiesis is primarily stimulated by erythropoietin (EPO), which is a glycoprotein 
hormone produced by the kidneys in response to low levels of oxygen. RBC development from 
the HSC is a multistep process in which many cell fate decisions must be made to specify not 
only to the myeloid lineage, but also to the erythroid lineage.  
The first erythroid lineage precursor, the proerythroblast, will receive multiple signals 
that cause morphological maturation, hemoglobin switching, hemoglobin accumulation, and 
ultimately enucleation. This multi-step process will produce biconcave discs, which have a large 
surface area-to-volume ratio that efficiently allows the diffusion of oxygen and carbon dioxide in 
and out of the cell. The flexible plasma membrane allows erythrocytes to maneuver through small 
capillaries, delivering oxygen to all parts of the body (Figure 1.4).  
 Without a nucleus, RBCs are incapable of repairing themselves after injury. Injured or 
old RBCs are cleared in the liver and spleen by phagocytosis. Macrophages are the primary 
recycler of RBC components after phagocytosis, such as the large amounts of iron that 
accumulated in hemoglobin. A typical RBC lifespan is 120 days, though injury or hemoglobin 
disorders can cause premature hemolysis. Loss of RBCs, or anemia, results in lower levels of 
oxygen (hypoxia). While hypoxia can occur naturally, when caused by loss of RBCS, it is 
extremely important to upregulate erythropoiesis to produce RBCs at a rapid rate. 
 
 
 
  
7 
Erythropoiesis: important cytokine and transcriptional regulation for the production of red blood 
cells  
Specification to the erythroid lineage relies on both concurrent and sequential expression of many 
transcription factors as well as cytokine signaling. Both external and internal signaling results in 
morphological changes of the proerythroblast to the erythrocyte, and hemoglobin production. 
Three important cytokines for erythropoiesis are SCF15, IL-316–18  
 
 
Figure 1.4. Signaling involved in erythroid maturation. Outline of cytokines and transcription 
factors involved in signaling for erythroid cell maturation. Image adapted from Wickrema & 
Crispino, Oncogene (2007), 26:6803-15. 
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and EPO19,20. While there are many important transcription factors involved in erythropoiesis, 
GATA1, FOG121 and KLF122,23 play a crucial role not only in maturation, but hemoglobin 
expression as well (Figure 1.5). 
 
Erythropoiesis: SCF, a hematopoietic cytokine 
Stem cell factor (SCF, also known as Kit ligand) exists both in a soluble and membrane-bound 
form and binds to the c-kit receptor. C-Kit signaling is important not only for erythroid progenitor 
proliferation, but also for HSC proliferation, mast cell function, melanogenesis, and 
spermatogenesis. C-kit is expressed on CD34+ hematopoietic progenitor cells and early erythroid 
progenitors, however it’s expression declines and ultimately disappears in late stage 
erythroblasts24. C-kit transcription is negatively regulated by direct binding of GATA-1 to the c-
kit promoter25. When SCF binds to the c-kit protein, it induces activation of PI3K resulting in 
increased proliferation of early and late erythroid progenitors, blast forming units, erythroid and 
colony forming units-erythroid, as well as terminally differentiated erythroid cells26,27. SCF 
signaling can inhibit cell cycle progression by inducing expression of Myc, which is involved in 
the final stages of erythroid maturation25,28. SCF also plays a role in promoting stress-induced 
erythropoiesis29.  
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Figure 1.5. Multiple transcription factors are involved in the production of eight types of 
blood cells. Transcription factors listed at the site of hematopoiesis in which their absence blocks 
the production of the resultant cells, as noted through conventional gene knockout studies. LT and 
ST-HSC, long-term and short-term hematopoietic stem cells; CMP, common myeloid progenitor; 
CLP, common lymphoid progenitor; MEP, megakaryocyte erythroid progenitor; GMP, 
granulocyte macrophage progenitor. From Orkin and Zon 6. 
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Erythropoiesis: EPO is a stimulant of erythroid progenitor differentiation 
Erythroid cell production occurs as a result of EPO signaling in the bone marrow. EPO, produced 
by the kidney, varies in concentration based on sensing oxygen intake and consumption in the 
organism. Levels are most commonly elevated in response to anemia and hypoxia30,31. Binding of 
EPO to EPO-receptors on the surface of erythroid progenitors triggers activation of multiple 
intracellular signal transduction pathways including STAT5 and PI3K whose signaling is 
essential for renewal divisions and differentiation of erythroid progenitors32–34. EPO and SCF 
activate common signaling pathways such as protein kinase B and the subsequent 
phosphorylation and inactivation of Foxo3a, while only EPO activates Stat5. Both Foxo3a and 
Stat5 independently promote erythroid differentiation. In bone marrow, EPO stimulates RBC 
production through two distinct mechanisms; increasing cell division of erythroblasts and 
accelerating the maturation of RBCs by accelerating hemoglobin synthesis35,36. This quickly 
results in an increase in the number of RBCs in the blood stream in a very short time span. 
 
Erythropoiesis: IL-3 is a myeloid specific differentiation factor 
Interleukin 3 (IL-3) plays an important role in the differentiation of myeloid cells in addition to its 
better-known role in immunity. IL-3 works in concert with other cytokines such as EPO, to aid in 
the growth and differentiation of myeloid progenitors. Studies in non-human primates have 
shown that IL-3 treatment results in an increase both early and late erythroid progenitors. 
Additionally, combination therapy of NHPs with IL-3 and EPO has shown a synergistic effect on 
erythropoiesis18. Experiments into culture conditions of erythroid lineage cells have found that 
IL-3 with SCF and EPO enabled not only the purification but the in vitro expansion of large 
numbers of erythroid progenitors from CD34+ peripheral blood cells37. 
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Erythropoiesis: GATA1, a master regulator of differentiation 
The transcription factor GATA-1 is required for terminal erythroid maturation and functions as an 
activator or repressor depending on gene context38.  GATA-1 is also required in other 
hematopoietic lineages. Much work has gone into understanding how a "master regulator" 
transcription factor coordinates tissue differentiation through a variety of DNA and protein 
interactions. Analysis of the promoter sequences of activated erythroid lineage genes revealed 
consensus sequences for SCL/Tal1 at GATA1-bound sites, revealing that GATA1 activation of 
these genes occurs in concert with the SCL/Tal1 co-regulator39–42. In erythroid cells, SCL/Tal1 
forms a complex with E2A, LMO2 and Ldb1 to form an activating complex with GATA143–45. 
The components of the GATA1 repressor complexes are much less clear and probably include 
FOG1, and the repressor Gfi-1b. 
 
Erythropoiesis: KLF1 is an essential erythroid transcription factor 
Kruppel like factor 1 (KLF1 or EKLF), is an essential zinc finger transcription factor that 
recognizes a subset of extended CACC box motifs whose locations are erythroid-restricted43,46. 
When binding sites were compared to GATA1 sites, almost half (48%) of the KLF1 sites were 
within 1 kb of GATA1 sites and few contained the SCL/Tal1 consensus sequence or overlapped 
with SCL/Tal1-GATA1 co-occupied sites suggesting that GATA1 and KLF1 may activate genes 
independently of SCL/Tal1 47,48. It is now believed that KLF1 is responsible for bringing 
transcriptionally active portions of the chromatin to transcription factories, rather than recruiting 
transcription machinery for the expression of erythroid specific genes49. 
In addition to maturation of erythroid cells, KLF1 is also responsible for regulating 
hemoglobin expression. This is accomplished by directly binding to the HBB promoter and 
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indirectly through upregulation of BCLl11A50,51. BCl11A forms a complex with GATA1, FOG1 
and the NuRD complex to upregulated β-globin expression. 
 
Erythropoiesis: FOG1, a teammate of GATA1 
FOG1 was identified as friend of GATA1, due to its action as a co-factor in GATA1 
transcription21. A zinc finger protein, FOG1, physically associates with the N finger of GATA-1 
via at least one of its fingers. In the absence of FOG1, there is a complete loss of progenitors 
committed to both the megakaryocyte and erythroid lineages, whereas myeloid-committed GMP 
progenitors were increased demonstrating the multiple roles FOG1 plays in hematopoiesis52. 
Point mutations that disrupt FOG1 binding affect normal erythroid and MK development in 
cellular assays, human patients, and engineered mutant mice53,54. FOG1 is required for the 
activation and repression of most GATA1-dependent genes54–56. Another partner of FOG1 the 
nucleosome remodeling and histone deacetylase complex NuRD, which binds to a small 
conserved motif at the extreme N-terminus of FOG1 57 has been shown to be involved in 
differential hemoglobin expression58. 
 
Erythropoiesis: the role of hemoglobin 
In 1840, hemoglobin was discovered by F. L. Hünefeld as the protein responsible for carrying 
oxygen in the blood59.  It was Fleix Hopp-Seyler who described hemoglobin’s reversible 
oxygenation and that iron in the globular protein allowed for hemoglobin’s oxygen carrying 
capacity60. Each heme group contains one iron atom and can bind one oxygen molecule through 
dipole forces allowing for the binding in high oxygen environments and release in low oxygen  
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Figure 1.6. Hemoglobin structure showing four heme molecules with attached iron. Sylvia S. 
Mader, Inquiry into Life, 8th edition, 1997. 
 
 
location. Hemoglobin will bind carbon dioxide in the periphery for transport and release from the 
lungs. Mammalian hemoglobin, as a tetramer of hemoglobin molecules can bind and carry up to 
four oxygen molecules (Figure 1.6). While also found outside of RBCs, hemoglobin functions as 
an antioxidant and a regulator of iron metabolism.  
Human hemoglobin has 6 distinct normal variants, each based on a phase of 
hematopoiesis. Each heterodimer contains one alpha-type globin and one beta-type globin, which 
change during fetal development. During early human embryonic development first primitive 
RBCs are derived from yolk sac blood islands 7,61. As the site of hematopoiesis moves throughout 
fetal development the type of hemoglobin expressed changes to meet the needs of the fetus. Early 
RBCs express embryonic globins alpha-type zeta (HBZ) and beta-type epsilon (HBE) globins, 
while fetal liver RBCs express alpha (HBA2 and HBA1) and beta-type gamma (HBG2 and HBG1) 
globins. During this stage of development the fetus is acquiring its oxygen from the maternal 
peripheral blood system, and therefore fetal hemoglobin, α2γ2 (HbF), which has a higher oxygen 
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affinity than adult hemoglobin, α2β2 (HbA), is required62. The final location of hematopoiesis, the 
bone marrow is colonized by HSCs around the mid stages of gestation, and it will reside there for 
the adult life of the individual. Bone marrow HSCs are the source of all definitive hematopoiesis, 
which results in 97% of RBCs expressing HbA and <1% containing HbF.  
Hemoglobin expression, while dependent on erythropoiesis, is not regulated by erythroid 
maturation. The site of hematopoiesis plays a larger role in the regulation in which hemoglobin 
molecules are expressed, rather than the maturation state of the cells. This is due to the variety of 
transcription factors involved in hemoglobin expression and their time/site specific expression. 
Hemoglobin switching, the process of changing from primarily γ-globin to β-globin expression 
within the chromosome 11 β-globin locus is an intricate process that begins in mid-gestation and 
it complete by about 6 months of age. Expression of both genes is under the control of the β-
globin locus control region and its dynamic interaction with associated transcription factor 
complexes allowing for specific globin expression. Hemoglobin switching is further addressed in 
Chapter 3. 
 
Erythropoiesis: morphology and surface markers of maturation 
Under normal conditions RBCs progress through multiple steps of maturation to go from an 
erythroblast to an erythrocyte. These steps will be explored in chapter 3. Briefly, cells are 
characterized morphologically based on size, hemoglobin content, and the size and appearance of 
the nucleus. As maturation continues the hemoglobin content in the cell increases while cell size 
decreases. All erythroid progenitors are capable of cell division until the stage of the normoblast, 
the smallest and last nucleate cell in the erythroid lineage. After the nucleus is extruded, the cell 
is known as a reticulocyte. Macrophages play a crucial role in nuclear extrusion, or the process of 
expelling the nucleus from the cell, by creating erythroblastic islands in the bone marrow63–65. 
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The resultant biconcave shape of the RBC increases the surface area of the cell for optimal 
oxygen exchange and allows for the deformability necessary to migrate through the 
microvasculature66.  
 Two surface markers are commonly used to assess maturation state of erythroid lineage 
cells in conjunction with morphology; they are Glycophorin A (CD235) and the transferrin 
receptor (CD71). CD235 is constitutively expressed on all erythroid cells while CD71 expression 
is limited to earlier progenitors. These markers will be discussed in further detail in chapter 3. 
 
The history and study of sickle cell disease 
Sickle cell disease: a brief history 
The first report of sickled cells in the United States was in 1910 from James Herrick who noticed 
these cells in blood specimens from Walter Clement Noel, a 20-year-old dental student from 
Grenada67. It took 12 years and four more reported cases for the disease, which commonly 
presents with anemia, to be named sickle cell anemia. Mechanistic studies revealed that 
deoxygenation of hemoglobin results in the sickling shape of affected individuals68. It was Linus 
Pauling who hypothesized that sickle cell anemia might be caused by abnormal hemoglobin in 
194569. Pauling was able to confirm this hypothesis by the differential migration of normal and 
sickle cell hemoglobin by non-denaturing gel electrophoresis70. Around this time, sickle cell 
anemia was revealed to be inherited in an autosomal recessive manner71.  
 It was not long before researchers began noticing differences in clinical manifestations of 
the disease. Studies of sickle cell disease patient relatives whom showed no symptoms of disease, 
determined that their RBCs also developed a sickling morphology when deprived of oxygen. This 
condition became known as “sickle trait”. It was confirmed in 1949 that those whom were 
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heterozygous for the mutation had the trait, while homozygous individuals had the more severe 
disease71. Sickle cell disease (SCD) is now used to refer to all individuals whom possess the 
sickle inducing mutation. It was also noted that infants, whom had high levels of HbF at birth, did 
not have symptoms of the disease until they were older72.  
The mutation causing the abnormal hemoglobin was identified in 1959 as a glutamine-to-
valine substitution at the sixth residue of the HBB polypeptide73. This amino acid change reveals 
a hydrophobic region when sickled hemoglobin is deoxygenated, allowing it to bind to a 
complementary hydrophobic site and polymerize (Figure 1.7). Small amounts of HbF can reduce 
polymerization of mutant HBB, reducing disease severity and improving the patient’s quality of 
life74. Hydroxyurea was first used for its HbF inducing properties in baboons in 198475 and 
humans in 199076. Multi-center studies proved its effectiveness and as the only FDA approved 
HbF inducing drug, hydroxyurea has been used ever since for treatment of sickle cell anemia77,78. 
 
Sickle cell disease: disease pathophysiology 
While most individuals express normal HbA, nearly 100,000 sickle cell disease patients reside in 
the United States (~0.03%) and eight percent of African Americans are carriers of the sickle 
hemoglobin (HbS, α2βS2) mutation. The clinical course of this disease is highly variable and 
affects many organs79. Upon deoxygenation, mutant HBB polymerizes and forms a rigid polymer 
due to the exposure of hydrophobic regions  
 
 
  
17 
 
 
Figure 1.7. Schematic of sickle cell disease demonstrating the cause and resulting 
complications due to the presence of sickled cells. From Steinberg, Forget, Higgs, and 
Weatherall, Disorders of Hemoglobin, 2nd edition, 200979. 
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created by the mutation. Polymer formation disrupts the cell membrane and cytoskeleton 
resulting in the characteristic change in erythroid cell shape, from a normal biconcave disc to a 
diseased sickle cell. This rigid HBB polymer reduces cell flexibility, often resulting in vaso-
occulusion and hemolysis (Figure 1.7).  
Vaso-occlusion, or the process of blocking blood vessels with sickled cells, is a 
predominant clinical manifestation of the SCD. In addition to the physical nature of rigid RBCs 
blocking the vasculature, sickle RBCs are more apt than normal RBC to adhere to endothelial 
cells in vitro80,81. Occlusive episodes result in pain that can be treated with hydration, analgesics, 
and blood transfusions to decrease the proportion of sickled RBCs. Numerous episodes can result 
in ischemic injury and permanent organ damage. 
Chronic hemolysis, or the rupture of a RBC, leads to the release of hemoglobin. Free 
hemoglobin has been shown to play a role in endothelial dysfunction through its ability to 
scavenge the second messenger signaling molecule, nitric oxide82. Oxidative stress is another 
result of hemolysis as is the release of iron from the cell. Other complications of the disease 
include but are not limited to priapism, autosplenectomy, stroke, chronic pain management and 
pulmonary hypertension. 
Despite the presence of HbS, individuals can present with a range in the severity of the 
disease phenotype. This indicates that deoxyHbS polymerization is necessary, but not sufficient 
to account for the heterogeneity of disease manifestations, which are genetically modulated and 
environmentally effected. Originally noted in infants, researchers have observed that individuals 
with less severe pathologies persist in making the fetal form of hemoglobin (HbF α2γ2), as adults. 
They also noted that the levels of HbF present may affect the amount of sickling and side-effects 
of the disease72,74,83. It is now understood that high amounts of HbF lower the concentration of 
sickle hemoglobin within a cell and neither HbF nor its mixed hybrid tetramer is incorporated 
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into the HbS polymer, resulting in less polymerization of the abnormal hemoglobin, which can 
lead to less severe disease phenotypes74. 
 
Sickle cell disease: haplotypes of SCD 
The persistence of HbF into adulthood has allowed for classification of patients based on the 
genetic markers linked with HbF expression. Using restriction site analysis, five distinct 
haplotypes of SCD have been identified linked: Senegal, Cameroon, Benin, Bantu (Central 
African Republic), and Arab-Indian84,85. Disease severity and patient outcome have been linked to 
particular haplotypes86. Severe disease outcome is seen most in individuals with the Bantu 
haplotype while intermediate disease severity is typical with Benin haplotypes. The Senegal and 
Arab-Indian haplotypes have milder disease symptoms86,87. As HbF levels within each haplotype 
varies, it implies that other factors than elements linked to the HBB gene cluster affect HbF 
concentration.  
 
Sickle cell disease: high levels of HbF, the case of HPFH and QTLs 
For reasons that are still being elucidated, there is a large amount of variance in HbF expression 
during adulthood due to both genetic88,89 and epigenetic factors90,91, with some individuals 
retaining high levels of HbF throughout their adult life. Quantitative trait loci (QTL) play a large 
role in the modulation of HbF expression. QTLs are genes or stretches of DNA, typically acting 
in trans, which are responsible for a quantifiable trait, such as hemoglobin expression. There are 
single nucleotide polymorphisms (SNPs) that have been identified by their ability to affect HbF 
expression in a patient specific manner. Four QTLs have been identified for their ability to 
increase HbF expression in adults; they are the Xmn1 restriction site 5’ to HBG2 on chromosome 
 
 
  
20 
11p92, a locus on chromosome 6q (HMIP)93, KLF151 and BCLl11A on chromosome 2p94. These 
single nucleotide polymorphisms, while occurring on other chromosomes, can modulate gene 
expression or alter protein interactions to increase HbF expression. While there are multiple 
QTLs that have been described, their effects on HbF levels are small compared to the variation 
seen in patients, suggesting that others are still to be found95.  
 
Sickle cell disease: methods to study SCD and screen for novel therapeutics 
As noted previously, HU has been demonstrated to increase expression of HbF in some patients, 
and while the exact mechanism is unknown, there is evidence to suggest that it may act through 
the induction of stress erythropoiesis96,97. Even modest levels of HbF have a profound effect in 
preventing polymerization of hemoglobin97. Since HU has variable effects, and can induce de 
novo copy number variants even at low doses, constant monitoring is required in every 
patient98,99. Hence, the search for HbF inducing drugs is on-going. Traditionally, prior to testing 
in in vivo models, researchers test HbF inducing drugs in two different cell types: K562, an 
erythroleukemia cell line or primary CD34+ cells from mobilized peripheral blood. Unfortunately 
both in vitro models have limitations.   
 K562 cells are an erythroleukemic immortalized cell line with both the potential to 
differentiate into erythroid- and megakaryocyte-lineage cells100. Treatment of K562 cells with 
sodium butyrate101 or hemin102 leads to increased expression of embryonic and fetal hemoglobin, 
with little expression of adult hemoglobin. Although predominantly expressing fetal globin103, 
this cell line has been widely used to study the therapeutic potential of HbF-inducing 
compounds104–107. Other commonly used human cells lines, such as KU812 and HEL cells, 
behave similarly to K562 cells, and also express primarily fetal and embryonic hemoglobin108. 
Collectively, these immortalized cell lines carry many chromosomal abnormalities, and in the 
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context of the large, diverse SCD population, represent the genetic background of single 
individuals, thus limiting the validity of findings.  
 To circumvent the issue of working with immortalized cell lines researchers also use 
primary CD34+ cells, which are most commonly isolated from the peripheral blood of patients 
whom have received granulocyte-colony stimulating factor cytokine treatment and CXCR4 
antagonist AMD3100109,110 in order to mobilize their HSC population. This process yields 
variable degrees of HSC mobilization even within the same individual111,112, is time consuming, 
expensive, invasive and reliant on having medical personnel available for the duration of the 
collection. While currently there is no evidence that mobilization can have long-term effects on 
the donor, further long-term studies are needed prior to researchers depending on these cells as a 
source for high-throughput drug discovery112. The main advantage of working with HSCs, 
defined as cells positive for the hematopoietic progenitor cell-surface marker CD34, is their 
ability to be differentiated into true adult erythroid cells with accompanying HbA expression. 
However, they have neither the capacity for extensive proliferation, nor uniform maturation with 
current culture methods. While one can look at a variety of individual responses using CD34+ 
cells from peripheral blood they have a limited lifespan and require patients to undergo HSC 
mobilization treatment every time new cells are required for study. The standard differentiation 
process involves multiple phases, yielding limited cell numbers and restricting the ability to run 
high-throughput screens.   
 Despite the difficulties of working with these two cell populations, they are still being 
used to identify and validate many new drugs. Some of these drugs include HDAC inhibitors113–
116, DNA-binding drugs which modify the formation of DNA/nuclear protein complexes to 
control gene expression117,118, and Cucurbitacin D (CuD)119 a ROS/p38 MAPK pathway 
modulator. While these molecules have shown promising results in changing the chromatin status 
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of the β-globin locus to allow for HbF expression, or generating cells with HbF expression via 
stress erythropoiesis, very few of these drugs have progressed beyond the pre-clinical stages of 
drug development, perhaps due to the context in which they are tested for efficacy.    
 
Mouse models of sickle cell disease 
For many years transgenic mice have been used to study human hemoglobin switching and 
erythroid maturation. As murine hemoglobin expression is different from humans, replacement of 
murine globins with human isoforms is imperative for the in vivo understanding of human 
hemoglobin switching. Studies of the pathophysiology of SCD has been facilitated by the 
development of a number of mouse models that express either a mixture of mouse globins with 
HbS, a super-sickling hemoglobin (e.g., SAD, NY1, S-Antilles mice), or human globin chains 
exclusively (e.g., Berkeley, NY1KO mice). Currently the mouse for studying human fetal-to-
adult globin switching is the Berkley-Townes mouse. This animal has all murine hemoglobins 
knocked out and replaced with overexpressed human versions resulting in murine globin 
promoters driving the expression of human HBA and HBBS120,121. While these mice are incredibly 
useful for studying development, their inbred background prevents full recapitulation of 
expressed hemoglobin diversity seen in human populations. Therefore it is necessary to study 
multiple people’s hemoglobin expression, not the single example given with the transgenic mouse 
models.  Variability in hemoglobin expression can be observed in cells expressing HbA, which is 
incredibly difficult to achieve in vitro. To observe adult hemoglobin expression in cells produced 
in vitro in an in vivo model must be generated resulting in humanized mice (addressed in further 
detail in chapter 3).  
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Induced Pluripotent Stems Cells (iPSCs) 
Pluripotency and its capabilities 
Reprogramming of somatic cells to a pluripotent state was originally achieved by the introduction 
of four transcription factors, Oct4, Klf4, Sox2 and c-Myc using a series of independent retroviral 
vectors122 to produce cells called induced pluripotent stem cells (iPSC). Following the 
reproduction and extension of these studies in both murine and human cells123,124, it is widely 
accepted that iPSC share many of the characteristics of embryonic stem cells (ESC), including 
gene expression profiles, epigenetic signatures and pluripotency125–128. iPSC and ESC are both 
examples of pluripotent stem cells, or cells that can give rise to all three germ layers. These cells 
have given scientists the ability to study disease progression outside of the patient, for these cells 
have the capacity to differentiate into any cell in the body. The directed differentiation of iPSC 
can reproduce the earliest stages of disease onset, a facet of disease progression not seen with 
conventional, transformed cell lines. With the ability to produce unlimited amounts of target cells 
and to differentiate into any cell type, iPSC have the potential to become a valuable tool for 
examining disease in the exact genetic context of the patient. 
 
Derivation of pluripotent cells from patient samples 
There have been many improvements to the methodology of iPSC generation, from individual to 
polycistronic viral vectors129–131, to non-integrating viruses and DNA-free techniques103,132–139. 
iPSC can be generated from mature somatic cells such as skin, hair cells140, and most recently, 
peripheral blood. The use of peripheral blood mononuclear cells in particular is favorable, as it 
only requires 4 mL to harvest sufficient numbers of mononuclear cells for the reprogramming 
process137,140–143 (Figure 1.8). Mononuclear cells can be expanded, frozen, shipped, and 
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reprogrammed to produce iPSC from patients worldwide. The practice of iPSC generation from 
peripheral blood mononuclear cells has the potential to facilitate the creation of large libraries of 
iPSC, from which researchers can model a plethora of diseases. 
 
Figure 1.8. Schematic of the production of induced pluripotent stem cells (iPSC) from a 
peripheral blood sample using the STEMCCA reprograming cassette. 
 
 
Disease modeling utilizing iPSCs 
Disease modeling with iPSC: an overview 
iPSC technology offers the prospect of an unlimited supply of material and is ideal for screening 
drugs against the genetic variations found in a patient population. It is also possible to obtain 
toxicity and efficacy data in multiple cell types from the same individual, all before human 
clinical trials144–146. Many steps must be taken before iPSC can become the dominant drug 
screening tool, including optimization of target cell differentiation, competent recapitulation of 
the disease in vitro, and creation of a scalable and automated assay for screening based on the 
disease phenotype147. These steps also depend on the ability to robustly and reproducibly generate 
high-quality cells, in both undifferentiated (iPSC) and differentiated (target cells) stages. 
Recently, iPSC have been used to model diseases as well as screen drugs for the treatment of 
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amyotrophic lateral sclerosis148, spinal muscular atrophy149, long QT syndrome150, familial 
dysautonomia151, familial TTR-amyloidosis152. Many researchers have already taken steps to 
demonstrate the efficacy of stem cell-generated cells in both modeling diseases and screening for 
novel therapeutics153, thus initiating iPSC into the drug discovery phase of therapeutic 
development.  
 
Drug screening with iPSC-derived cells 
The utilization of iPSC for drug screening presents researchers with the opportunity to explore the 
effects of a drug on multiple cell types from the same individual, thus examining toxicity well 
before the initial phases of clinical trial. Common side effects seen during drug testing are due to 
toxicity damage of tissues of the peripheral nervous system, the liver, and the heart, making 
examination of these systems crucial for drug screening in vitro. Given the pluripotent nature and 
flexibility of iPSC, it is possible to create a complete “in vitro clinical trial” which would allow 
for both the testing of novel therapeutics in target cells as well as toxicity testing in peripherally 
affected tissues (Figure 1.9). There are many researchers working on the optimal differentiation 
conditions to generate these cells and many have screened for toxicity in neurons154, 
hepatocytes155, and cardiomyocytes150,156,157. The ability to use iPSC for in vitro disease modeling, 
high-throughput drug screening, as well as drug toxicity screening, may ultimately help to reduce 
the timeline from the identification of novel therapeutics to FDA approval for treatment in 
patients. 
 
 
 
 
 
 
  
26 
Figure 1.9. Drug screen with cells derived from iPSC allows for in vitro screening for both 
efficacy and toxicity. 
 
 
 
 
 
In vitro disease modeling of SCD with iPSC 
As the mutation for SCD is located on the β-globin gene, expression of HbA is required to view 
the disease phenotype in vitro. Most laboratory models for SCD express HbF, forcing researchers 
to induce a switch from HbF to HbA expression, a process that has proven elusive. Therefore, for 
many years, sickle cell researchers have primarily focused on two objectives; firstly, the creation 
of an in vitro model of sickle cell disease whereby HbS expressing cells can be produced and 
characterized, and secondly, the identification of novel pharmacological agents that are capable of 
HbF induction in HbS expressing cells. Both goals have been met with limited success. To date, 
the field is still lacking an in vitro model system that can produce sufficiently large numbers of 
adult red blood cells, and while potential novel therapeutics for SCD have been identified, HU is 
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still the only drug used in the clinic. The advent of iPSC has renewed vigor in pursuing these 
goals as the use of iPSC will permit researchers to examine multiple cell lines representing 
patients world-wide and strengthen our knowledge of how genetic variations result in variance in 
SCD pathophysiology and drug responsiveness (Figure 1.10).  
 SCD is an ideal disease to model with iPSC because although all patients suffering with 
SCD share the same mutation, variability in the severity of the disease is common, illustrating the 
importance of visualizing SCD through a variety of genetic backgrounds. Traditionally the 
genetic complexity of SCD is explored by collection of PB-CD34+ cells from multiple 
individuals. These cells undergo multiple differentiation phases to produce enucleated RBC for 
analysis119,158,159. The difficult culture conditions for progenitor cell expansion and then 
subsequent specification and maturation160–162, as well as the lack of markers for HSCs during this 
process impedes their use in large scale119,163,164. This is especially problematic when trying to 
model SCD pathophysiology within families, let alone worldwide. 
 Since the advent of ESC and iPSC technology, there has been interest in achieving 
efficient differentiation of pluripotent cells to RBC, particularly cells that express HbA. To 
achieve this researchers have employed numerous methods including, but not limited to, 
embryoid bodies165–168, co-culture with stromal layers169–171, and 2D feeder/serum free 
conditions172–175.  Some of the most critical limitations of these methods are irreproducibility, the 
possibility of cross-species contamination, low cell numbers, and a lack of cells expressing HbA. 
2D feeder/serum-free differentiation methodologies remove concerns regarding cross-species 
contamination seen with co-culture methods and the lack of reproducibility with embryoid body 
differentiation, but the production of cells in sufficient numbers still remains an issue. The use of 
an aryl hydrocarbon agonist for the efficient production of hematopoietic progenitors will be 
illustrated in Chapter 2. The ability to achieve large-scale expansion of a progenitor population in  
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Figure 1.10. The potential of disease modeling with iPSC includes derivation and study of 
the affected cells as well as high throughput screening of potential therapeutics. 
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relatively short time frame suggests that progenitors generated in this way may be used as a 
staging-point for large-scale differentiation of iPSC-derivatives into the erythroid lineage. Even 
with the efficient derivation of large numbers of iPSC derived erythroid cells, these cells produce 
HbF and not HbA, suggesting they are a product of primitive hematopoiesis.  
 As seen with a variety of cell types, end-stage, in vitro differentiated cells produced from 
an embryonic source, such as ESC and iPSC, tend to predominantly express fetal proteins rather 
than adult proteins176. This has been observed in the erythroid lineage, where enucleated red 
blood cells primarily express HbF, rather than HbA166,168,171,175,177–181. It has been reported, 
however, that stem cell-generated red cell progenitors will enucleate and mature to express HbA 
when transplanted into recipient mice182, suggesting that there are unknown factors, such as the 
proper niche or transcription factors that are required in order for hemoglobin switching to occur, 
and that a better understanding of final steps of in vivo hemoglobin switching may allow 
researchers to generate this switch in vitro.  
Specific Aims 
The goal of this project is to harness the directed differentiation of iPSCs to produce an unlimited 
supply of sickle cell disease-specific erythroid-lineage cells that can be utilized to study the 
expression of HbF. For this proposal, I will use a novel, excisable reprogramming vector able to 
generate clinical grade iPSCs free of any residual reprogramming transgenes. I propose to 
characterize erythroid lineage cells derived from multiple SCD-specific iPSC lines for 
hemoglobin expression, response to HU treatment, and their maturation capabilities.  This system 
allows for the examination of differences in a variety of individuals with varying in vivo HbF 
levels, as well as the in vitro HbF response potential therapeutics.   
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CHAPTER 2: 
MODULATION OF THE ARYL HYDROCARBON RECEPTOR DIRECTS 
HEMATOPOIETIC PROGENITOR CELL EXPANSION AND DIFFERENTIATION 
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Abstract 
The evolutionarily conserved aryl hydrocarbon receptor (AhR), a member of the basic helix-loop-
helix Per-ARNT-Sim family, has been studied for its role in environmental chemical-induced 
toxicity. However, recent studies now demonstrate that the AhR may regulate the hematopoietic 
and immune systems during development in a cell-specific manner. As a roadmap for assessing 
the possible role of the AhR receptor in hematopoietic cells, we performed an in silico analysis of 
transcriptional profiles of 71 primary human hematopoietic cell isolates which indicated AhR-
upregulation at both the hematopoietic stem cell and bipotential hematopoietic progenitor (HP) 
stages. This result, together with the absence of an in vitro model system enabling production of 
large numbers of primary human HPs capable of differentiating into megakaryocyte- and 
erythroid-lineage cells, motivated us to determine if AhR modulation could facilitate both HP 
expansion and megakaryocyte and erythroid cell differentiation. Here we show that a functional 
AhR is expressed in hematopoietic cells at the HP stage of development. Our chemically defined, 
serum and feeder-free directed differentiation strategy employs a potent AhR ligand, which 
allows for the capture in culture and expansion of populations of HPs, megakaryocyte- and 
erythroid-lineage cells. Further modulation of the AhR in these cells directs cell fate, with AhR 
agonism permissive to erythroid differentiation and antagonism favoring megakaryocyte 
specification. These results highlight the development of a new platform for studying human red 
blood cell and platelet development, and demonstrate that the AhR plays a critical physiological 
and functional role in hematopoiesis.  
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Introduction    
The aryl hydrocarbon receptor: environmental roles  
The AhR is a member of the evolutionarily conserved Per/ARNT/SIM (PAS) family of 
transcription factors183. It is the only PAS family member activated by either endogenous or 
exogenous ligands. PAS proteins contribute to several important physiological processes184–187. 
When bound by a ligand, cytosolic inactive AhR is released from its chaperone complex and 
binds to the AhR nuclear translocator (ARNT) and translocates to the nucleus. The AhR/ARNT 
complex binds to a specific DNA sequence, TnGCGTG, known as both the dioxin or AhR 
response element (DRE or AhRE). Binding increases transcription of cytochrome P450 genes, 
CYP1A1 and CYP1B1, which are crucial for the metabolism of xenobiotic toxins for removal. 
AhR/ARNT signaling is repressed by also upregulating expression of the aryl hydrocarbon 
receptor repressor, which will compete for binding of ARNT, as part of a negative feedback loop 
(Figure 2.1). Historically, the evolutionarily conserved AhR was studied in the context of its 
activation by a variety of ubiquitous environmental pollutants including dioxins, polychlorinated 
biphenyls, and polycyclic aromatic hydrocarbons, and subsequent transactivation of cytochrome 
P450-encoding genes188–198 (Figure 2.2). Recently, the AhR field has undergone a major 
paradigm shift following the demonstration that the AhR plays important physiological roles in 
the absence of environmental ligands197–204. 
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Figure 2.1. Ligand binding of the AhR induces a signaling pathway resulting in the 
upregulation of AhR specific gene targets. Upon ligand binding AhR dissociates from its 
cytoplasmic chaperone complex and binds the aryl hydrocarbon nuclear translocator (ARNT). 
This reveals a nuclear localization sequence that allows AhR/ARNT/ligand to enter the nucleus 
and bind to dioxin response elements (DRE), which results in the upregulation of gene expression 
of gene targets necessary for the metabolism of toxins. McIntosh, BE, et al. Annu. Rev. Physiol. 
(2010) 72:625-645. 
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Figure 2.2. Environmental toxins known to be AhR ligands. A common example of a 
polychlorinated dibenzodioxins is dioxin, also known as TCCD. Polycyclic aromatic 
hydrocarbons (PAH) can be found in atmospheric pollutants. Widely used as dielectric and 
coolant fluids in transformers, capacitors and electric motors, polychlorinated biphenyls (PCBs) 
are now banned in the United States. 
 
 
The aryl hydrocarbon receptor: non-environmental roles 
Several studies demonstrate that the AhR contributes to regulation of autoimmune 
responses197,198,200–203,205, inflammation203,206, cell growth207, cell migration208–210, apoptosis211–214 
and cancer progression215–219. Specifically with regard to hematopoietic cells, studies demonstrate 
that the AhR regulates development of Th17 cells, regulatory T cells subsets, and gut-associated 
T cells197–204,220. Importantly, recent breakthrough studies suggest that the AhR plays a critical 
role in nominal HSC growth and differentiation160,221. For example, AhR-/- mice are characterized 
by an increased number of bone marrow HSCs221 and a commensurate increased propensity to 
develop lymphomas222. These insights led to the hypothesis that the AhR, activated by 
endogenous ligands, regulates stem cell growth and/or differentiation223. Despite these early 
results, little is known about the effects of AhR modulation on the development of Mk- or 
erythroid-lineage cells from bipotential progenitors. Involvement of AhR in this process is 
suggested by decreased numbers of erythrocytes and platelets in young AhR-/- mice and the 
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skewing of the blood cell repertoire towards myeloid and B lineage cells as AhR-/- mice 
age221,224,225. 
Development of blood lineages from a stem cell 
The differentiation of HSCs into all eight blood cell lineages is a critical and tightly regulated 
physiological process6. Disruption of this regulation can have a profound downstream effect on 
multiple hematopoietic cell types, potentially leading to a myriad of blood cell disorders from 
leukemia to stem cell exhaustion221,226,227. However, definition of the molecular mechanisms that 
control specification of primary human blood cells has been hampered by the lack of a model 
system in which sufficient numbers of stem or progenitor cells can be grown and the absence of 
practical and efficient techniques for directing differentiation of hematologic progenitors into end 
stage cells. For example, several teams have published proof-of-principle examples of the 
derivation of megakaryocytes (Mk)133,228,229 and erythroid-lineage cells171,173,228 from embryonic 
stem cells (ESC) and induced pluripotent stem cells (iPSC). Many of the attempted 
methodologies have resulted in technically difficult protocols that produce insufficient yields for 
extensive studies. Development of a model system which results in robust expansion of these cell 
populations and with which molecular signals driving cell differentiation can readily be studied is 
needed.  
Our conceptual approach to addressing this need was to mimic in vitro the natural 
sequences of blood cell development in vivo to derive the number and range of cells types needed 
for the creation of a genetically tractable iPSC-based platform.  Key components of this new 
platform, as shown here, include the definition of feeder-free, chemically defined conditions 
under which megakaryocyte-erythroid progenitor cells (HPs) can be established and a stimulus 
(aryl hydrocarbon receptor/AhR hyper-activation) which results in a dramatic expansion of the 
HP population and the production of virtually unlimited numbers of Mk- and erythroid-lineage 
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cells from iPSCs. The in vitro system described herein allows the capture in culture and 
expansion of pure populations of HPs that exist transiently during in vivo development of end 
stage megakaryocytes and red blood cells. This platform allows unprecedented efficiency and 
consistency in the derivation of bipotential hematopoietic progenitors and their progeny from 
pluripotent stem cells using AhR modulation and reveals that AhR activity can drive bipotential 
progenitor cell fate, establishing the AhR as a key player in hematopoietic differentiation. In 
addition to demonstrating a critical role for the AhR in HP, Mk, and RBC development, the 
platform provides an important and genetically tractable system for studying blood cell 
differentiation at multiple, defined stages of development. The platform presented here represents 
a significant step towards the in vitro production of virtually unlimited numbers of therapeutic, 
patient-specific RBCs and platelets.   
Materials and Methods 
 
iPSC derivation and culture: iPSC derivation was achieved using the hSTEMCCA lentiviral 
vector as previously described130,143.   
 
Directed differentiation of iPSCs into hematopoietic cells: iPSCs were plated onto matrigel 
coated 6-well plates in iPSC media conditioned on iMEFs for 24 hours and supplemented with 2 
ng/mL Rho Kinase Inhibitor and 20 ng/mL bFGF.  After two days, iPSC media was replaced with 
media cocktails designed to initiate hematopoietic specification: D0-1 media: RPMI (Invitrogen 
A1049101) supplemented with 5 ng/mL hBMP-4 (R&D 314-BP-010), 50 ng/mL hVEGF (R&D 
293-VE-010), 25 ng/mL hWnt3a (R&D 287-TC-500) and 10% KOSR; D2 media: RPMI 
supplemented with 5 ng/mL hBMP-4, 50 ng/mL hVEGF, 20 ng/mL bFGF and 10% KOSR; D3 
media: StemPro 34 (Invitrogen 10639011), 5 ng/mL hBMP-4, 50 ng/mL hVEGF, and 20 ng/mL 
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bFGF; D4-5 media: StemPro 34, 15 ng/mL hVEGF, and 5 ng/mL bFGF; D6 media: 74% IMDM 
(Invitrogen 12330061), 24% Hams F12 (Mediatech 10-080-CV), 1% B27 supplement (Invitrogen 
12587-010), 0.5% N2-supplement (Invitrogen 17502-048), 0.5% BSA (Sigma A3059), 50 ng/mL 
hVEGF, 100 ng/mL bFGF, 100 ng/mL hSCF (R&D 255-SC-010), 25 ng/mL hFlt3 Ligand (R&D 
308-FKN-005);  D7 media: 74% IMDM, 24% Hams F12, 1% B27 supplement, 0.5% N2-
supplement, 0.5% BSA, 50 ng/mL hVEGF, 100 ng/mL bFGF, 100 ng/mL hSCF, 25 ng/mL hFlt3 
Ligand, 50 ng/mL hTPO (Genentech G140BT), 10 ng/mL IL-6 (R&D 206-IL-010), 0.5 U/mL 
hEPOgen (Amgen) and 0.2 µM 6-formylindolo[3,2-b]carbazole (FICZ) (Santa Cruz SC300019).  
After Day 7, 0.5ml of Day 7 media was added to the culture daily without aspirating the media 
from the previous day.  All base media mixes included 2 mM L-Glutamine (Invitrogen 
25030081), 4x10-4 M Monothioglycerol (Sigma M1753), 100 mg/mL Primocin, and 50 µg/mL 
Ascorbic Acid.  Cells in suspension were collected and assayed at Days 10-15 or split for long-
term culture.   
 
Methylcellulose assays:  Non-adherent day 15 HPs were collected and plated in methylcult 
H4034 Optimum (Stem Cell Technologies, 4034) at a density of 56,000 cells per 3 mL of 
methylcult.  The methylcult and cell mixture was plated in 35 mm culture dishes as per 
manufacture's instructions.  Resultant colonies were scored on day 12 and classified as mixed, 
myeloid, or erythroid in origin.   
 
Mass spectrometry analyses: Whole blood was diluted 1:500 in ESI buffer and analyzed directly.  
iPSC-derived erythroid-lineage cells were lysed with the addition of formic acid (0.8%) and the 
resulting solution was passed through a C18 spin column. Proteins were eluted with 60% 
acetonitrile/0.3% formic acid/water and assayed.   
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Megakaryocyte- and erythroid-lineage specification of HPs: Mk-lineage cells were generated 
from Day 15 HPs by first washing the cells and placing them in Mk specification media 
containing IMDM, 0.5% BSA, 10 mg/mL NTPs and dNTPs (Invitrogen), 40mg/mL LDL (Sigma 
L8292), 200 mg/mL human holo-transferrin (Sigma T0665), 10 mg/mL human insulin (Sigma 
I3536), 50 mM 2 ME, and 100 ng/mL human TPO.  Erythroid-lineage cells were generated from 
Day 15 HPs by first washing the cells and placing them in erythroid specification media 
containing IMDM, 10% Plasmanate (Talecris Biotherapeutics Inc. NC27709), and 3 U/mL 
human EPO.   
 
Lentiviral vector generation and application:  PCR primers were designed to amplify the MMTV-
DRE (mouse mammary tumor virus / dioxin response element region from the murine CY1A1 
gene) promoter region from AHR activity reporter construct pGudLuc1.1, with integrated SpeI 
and NotI cut sites at the 5’ and 3’ ends respectively. The restriction enzyme digested PCR product 
was then inserted into the pHAGE2 lentiviral Ef1α-dsRed(NLS)-IRES-ZsGreen plasmid and the 
pHAGE2 lentiviral Ef1α-destabilized ZsGreen by excision of the Ef1α promoter and ligation of 
the SpeI and NotI digested MMTV-DRE.  Additionally, the AHR repressor was cloned into the 
pHAGE2 lentiviral Ef1α-dsRed(NLS)-IRES-ZsGreen.  Primers were designed to amplify the 
f.heteroclitus AHRR coding region from an HPV422-based construct, with NotI / BamHI cut 
sites incorporated at the 5’ and 3’ sites respectively. VSV-G pseudotyped lentivirus was packaged 
and concentrated as previously described. Cells were infected overnight and subsequent dsRed 
and ZsGreen gene expression was monitored by fluorescence microscopy and flow cytometry as 
indicated in the text. 
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AHR small molecule competition assays:  6-formylindolo[3,2-b]carbazole (FICZ), an AHR small 
molecule agonist, and CH223191, an AhR competitive inhibitor, were provided by David Sherr’s 
laboratory.  CH223191 was added to cultures at Day 6 at 5 mM (1x) and 2.5 mM (0.5x).  0.2 mM 
FICZ was added to cultures at Day 7 and media was added daily.  DMSO was used as a vehicle 
control.   
 
Quantitative RT-PCR: RNA was extracted using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions and DNase treated using the DNA-free kit (Ambion AM1906).  
Reverse transcription into cDNA was performed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems 4368814).  Quantitative (real time) PCR amplification of 
cDNA was performed using Taqman probes for AHR (Hs00169233_m1), CYP1B1 
(Hs002382916_s1), HBA (Hs00361191_g1), HBB (Hs00758889_s1), HBG (Hs01629437_s1), 
vWF (Hs00169795_m1), PF4 (Hs00427220_g1), NF-E2 (Hs00232351_m1) and CD62P 
(Hs00927900_m1) and run on the Applied Biosystems StepOne machine.  Relative gene 
expression was normalized to B-actin (Hs99999903_m1).  
 
Flow Cytometry:  Roughly 105 cells were collected, spun, and re-suspended in 0.5% BSA in PBS.  
Samples were incubated for 30 minutes at ambient temperature with human antibodies including 
CD41a-FITC (BD 555466), CD235-PE (BD 555570), CD71-FITC (BD 555536), washed and 
spun at 3300 rpm for 7 minutes, and re-suspended in 0.5% BSA in PBS with 1 mg/mL Propidium 
Iodide.  Samples were run on a BD FACScalibur using Cellquest Pro software and analyzed via 
FloJo 8.7.  For ploidy analysis, cells were treated with 1.5% NP-40 (Boston Bioproducts P-872) 
and 62.5 mg/mL Propidium Iodide in PBS immediately before FACScalibur interrogation.  For 
murine bone marrow, samples were first incubated for 5 minutes at ambient temperature with 
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murine conjugated antibody CD16/32 (BD 553142) before a 30-minute incubation with c-Kit-PE 
(BD 553355), CD41a-FITC (BD 553848), Ter119-PE (BD 553673). For cell viability assays, 2-3 
x 105 cells were collected and resuspended in 8.8 mg/mL Hoechst 33342 in PBS supplemented 
with 5% FBS.  Samples were then incubated in the dark at 37°C for 15 minutes, washed, and re-
suspended in 1 mg/mL Propidium Iodide in 5% FBS.  Samples were run on an LSR-II machine 
with FACSDiva software and analyzed via FloJo 8.7.        
 
Gene expression analysis:  The data analyzed correspond to the RMA-processed, batch-
normalized, Affymetrix expression profiles downloaded from the dMap website 
(www.broadinstitute.org/dmap). This includes the expression levels of 8968 Entrez-annotated 
genes across 212 experiments representing 15 distinct populations (38 sub-populations) of 
hematopoietic cells. The data was projected onto the space of 37 manually curated AhR targets, 
plus AhR itself, and 72 experiments corresponding to 5 populations (11 sub-populations), 
defining the HSC-to-Mk/erythroid differentiation path. The genes were sorted based on 
hierarchical clustering with 1-Pearson correlation as the distance metric, and average linkage as 
the agglomeration rule230 (Figure 1A). The normalized expression level of AhR within each cell 
population (sub-population) was computed and visualized by means of box-and-whiskers plots 
(Figure 1B). For each population, the plot reports the median (thick mid line), the middle half (the 
box), and the Interquartile Range (IQR, the distance between the "whiskers") of the distribution 
of AhR values. The difference in the expression level of AhR among cell populations was tested 
by standard analysis-of-variance (anova)231.                                                                                                                                              
 
Statistical Analysis:  Results are presented as the mean ± the standard deviation of experiments 
performed in triplicate.  Statistical significance was confirmed using the Student’s t-test.  
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Results 
 
Analysis of human hematopoietic cell differentiation genomic mapping (dMap) data suggests a 
role for AhR in normal hematopoietic specification 
As a guide for assessing the possible role of the AhR receptor in hematopoietic cells, we analyzed 
the “dMap” dataset (www.broadinstitute.org/dmap)232 a publicly available compendium of 
expression profiles from 71 distinct purified populations of human hematopoietic cells. For our 
purposes, we focused on the HSC-to-Mk/erythroid differentiation path and we analyzed the 
expression of a manually curated list of putative AhR target genes. Hierarchical clustering was 
carried out to evaluate the co-expression patterns of AHR and these genes. This analysis revealed 
up-regulated AHR mRNA expression in HSCs and MEPs (Figure 2.3). Erythroid cells clustered 
into 2 groups. Earlier phase erythroid cells maintain elevated expression of the AHR and genes 
upregulated in MEPs. Later phase erythroid cells exhibited a largely reciprocal pattern. AHR 
levels were consistently upregulated in Mks. The levels of 21 genes, including several of 
considerable import to stem cells (e.g., c-Myc, EGR1, ALDHA1) were significantly correlated 
with AHR levels (false discovery rate <0.004). Other important hematopoietic-specific genes such 
as NFE2, a critical regulator of both the erythroid and  
 
 
 
  
42 
 
Figure 2.3. Analysis of human hematopoietic cell differentiation genomic mapping (dMap) 
data reveals a role for AhR in normal hematopoietic specification. (A) Computational 
analysis of comprehensive microarray data obtained through the Broad Institute’s Differential 
Map Portal (dMAP). The genes were sorted based on hierarchical clustering with 1-Pearson 
correlation as the distance metric, and average linkage as the agglomeration rule230. (B) The 
normalized expression level of AHR within each cell population (sub-population) was computed 
and visualized by means of box-and-whiskers plots. For each population, the plot reports the 
median (thick mid line), the middle half (the box), and the Interquartile Range (IQR, the distance 
between the "whiskers") of the distribution of AHR values. The difference in the expression level 
of AHR among cell populations was tested by standard analysis-of-variance (anova)231. S. Monti 
contributed this figure.  
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Mk lineages were negatively correlated with Ahr expression. These results indicate that Ahr 
expression is evident in hematopoietic progenitor cells and suggest that the AhR may play  
The aryl hydrocarbon receptor (AhR) agonist 6-formylindolo[3,2-b]carbazole (FICZ) allows for 
the exponential expansion of iPSC-derived HPs. 
The clinical translation of iPSC-based technologies will require many modifications to improve 
the efficiency of generation and the safety profile of iPSC-derived cells. Using a novel, feeder 
cell-free, chemically-defined system for the production of hematopoietic progenitor cells from 
human iPSCs that is not beholden to the use of stromal cell lines or xenogeneic agents, our 
primary goal was the production of large numbers of clinically relevant, high purity 
hematopoietic cells. Our approach follows the roadmap provided by the developing embryo. 
Since ESC and iPSC resemble pluripotent, undifferentiated cells of the early blastocyst embryo, 
the signals active in the early embryo were harnessed to direct the differentiation of iPSC in vitro.  
Due to the known variability in the formation of human embryoid bodies229, this protocol utilizes 
a 2D culture system optimized to produce bipotential hematopoietic progenitor cells within 10-15 
days (Figure 2.4A). Because of the expression of AHR mRNA early in the HP differentiation 
process (Figure 2.3), a strong AhR agonist, FICZ, was added on Day 7.  
In this system, differentiating iPSC produce an endothelial-like adherent layer from 
which non-adherent CD45+ hematopoietic cells emerge beginning at Day 7 (data not shown). 
Days 7-15 are characterized by the rapid outgrowth of non-adherent cells (Figure 2.4A and 
2.5A).  As judged by immunophenotyping at Day 15, greater than 50%  
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Figure 2.4. The feeder-free, chemically defined production of hematopoietic progenitor cells 
(HPs) from iPSCs produces populations of cells that express markers of both 
megakaryocyte and erythroid lineages. (A) Differentiation strategy from iPSC to HP stage. 
Phase contrast images (10x) of cultures depicting morphological changes and the production of 
both an initial adherent layer followed by non-adherent HPs. (B) Representative FACS analysis 
of Day 15 HPs that co-express CD235-PE (red cells) and CD41-FITC (megakaryocytes). (C) 
qPCR analysis of undifferentiated iPSCs vs. Day 15 HPs. Relative gene expression was 
normalized to β-actin. Data is the average of 3 independent experiments + SD. *P<.05.  (D) 
Representative FACS analysis of Day 15 HPs that have been exposed to either erythroid- or 
megakaryocyte-specific specification media for 5 days. Results shown represent work done by 
both S. Rozelle (A, B, C) and B. Smith (D). 
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of these cells co-express CD235-glycophorin A (erythroid lineage) and CD41-integrin aIIb (Mk 
lineage) suggesting that bipotential HPs had been generated (Figure 2.4B). When placed in 
colony forming assays, this total, unsorted population of cells produced roughly equal numbers of 
mixed, myeloid- and erythroid-lineage colonies suggesting the presence of bipotential HPs, as 
well as committed Mk- and erythroid-lineage cells (Figure 2.5B). In comparison to 
undifferentiated iPSCs, these cells also significantly upregulate globin genes characteristic of 
erythroid-lineage cells and PF4, CD62P, and NFE2 genes characteristic of Mk-lineage cells 
(Figure 2.4C). Note that the timeframe to generate what phenotypically appear to be HPs is 
significantly shorter than that noted in previously described protocols171,173 and that no 
fractionation or further manipulation of the cells is required. Importantly, maintenance of HP 
cultures in erythroid specification media containing EPO, or Mk specification media containing 
TPO, resulted in a final fate choice leading to the appearance of distinct populations of CD235+ 
/CD41- erythroid- or CD41+/CD235- Mk-lineage cells respectively (Figure 2.4D). These results 
are consistent with the presence of functionally bipotential HPs. 
A crucial roadblock in the translation of iPSC technology is the ability to produce 
sufficient, clinically relevant quantities of cells.  Even for basic research studies, the numbers and 
quality of hematopoietic cells that can be produced through the directed differentiation of iPSC 
can be limiting233. With the outgrowth of HPs by day 15 of culture, we were presented with the 
possibility that ongoing AhR activation could continue to drive HP expansion.  Here, we 
demonstrate that the AhR agonist FICZ has the ability to allow for the exponential expansion of 
iPSC-derived HPs.  In comparison to  
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Figure 2.5. The aryl hydrocarbon receptor (AhR) agonist FICZ inhibits apoptosis and 
allows for the exponential expansion of iPSC-derived HPs. (A) Representative FACS analysis 
of live versus dead or dying cells (PI vs. Hoechst) from D15 HPs + FICZ. Plots were gated first in 
FSC vs. SSC and then from that population for PI+ and PI- Hoechst+.  (B) FICZ increases the 
population of live cells as delineated by FSC and SSC and decreases the number of compromised 
or apoptotic cells. For the live cell gate, data is the average of 3 independent experiments + SD: 
*P<.01; For the apoptotic cell gate, data is the average of 3 independent experiments + SD: 
*P<.02. (C) EdU (5-ethynyl-2’-deoxyuridine) proliferation assay comparing D15 HPs + FICZ. 
Following FICZ stimulation at day 7, EdU incorporation into treated HPs was significantly 
increased compared to untreated controls indicative of increased proliferation. Data is the average 
of 3 independent experiments + SD. *P<.01. (D) Representative phase contrast images of HP 
population + FICZ.  (E) Growth curve of D15 HPs + 0.2mm FICZ.  Cells were counted manually 
using trypan blue exclusion.  Graphical data and the associated statistics are the result of 3 
independent experiments per group. Results shown represent work done by S. Rozelle (D, E), A. 
Leung (A, B), and G. Murphy (C, E).  
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untreated control samples, FICZ-treated HPs demonstrate significantly less cell death as judged 
by propidium iodide and Hoechst dye exclusion (Figures 2.6A&B). In contrast to untreated cells 
in which 500,000 HPs yielded 4 million cells (8 fold increase), FICZ-treated day 15 HPs 
demonstrated logarithmic expansion such that FICZ treatment of 500,000 HPs yielded 300 
million cells (600 fold increase) within 10 days (Figure 2.6C). 
AhR mediates the expansion and specification of bipotential hematopoietic progenitors 
The results presented above strongly suggest that AhR hyper-activation drives human HP 
expansion. To further test this hypothesis, AhR expression and functionality in both 
undifferentiated iPSCs and differentiated HPs were investigated. Little or no AhR receptor 
protein was detected in human iPSC by Western blotting (Figure 2.7A). However, a significant 
increase in expression of the prototypic AhR target gene, CYP1B1 as seen by qPCR 72 hours 
after treatment with 0.2 µM FICZ suggesting that iPSC express AhR, but at levels below those 
detectable in Western blots (Figure 2.7B). Similarly, AhR protein was not detected in day 15 
HPs. However, treatment of day 15 HPs with FICZ significantly induced CYP1B1 expression 
(Figure 2.7B). Similar data were obtained with two other AhR agonists, β-naphthoflavone (BNF) 
and the prototypic environmental AhR ligand, 2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD) 
(Figure 2.8). In contrast to iPSCs or day 15 HPs, AhR was robustly expressed in day 30 and day 
60 HPs (Figure 2.7A).  
To quantify baseline AhR transcriptional activity, presumably enforced by an 
endogenous AhR ligand, we cloned a human AhR-driven promoter234,235 into a lentivirus reporter 
vector that encodes for dsRed and ZsGreen (Figure 2.9A). This dual gene AhR- 
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Figure 2.6. Characterization of early-stage iPSC-derived hematopoietic progenitor cells. (A) 
Flow cytometry characterization of adherent and floating cell populations in D12 hematopoietic 
cultures.  The cells were examined for a panel of markers representing early-stage hematopoietic 
(CD43, c-kit, CD34) and endothelial markers (Tie2, KDR).  These results indicate that floating 
cells are enriched for CD43 positivity, a marker of committed definitive hematopoietic 
progenitors, while the adherent layer contains a high proportion of cells positive for early 
hematopoietic markers c-kit and CD34, in addition to endothelial markers Tie2 and KDR.   (B) 
Colony forming cell assays from unsorted D15 non-adherent cell populations in which 28,000 
cells per assay were grown in methylcellulose with hematopoietic growth factors for 12 
days.  Data are averages of three independent experiments and graphed as a percentage of total 
colonies formed. (no statistical difference was noted between colony types). Results shown 
represent work done by A. Leung (A) and S. Rozelle (B). 
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driven reporter construct allowed for the normalization of transduction efficiency, correction for 
auto-florescence, and the quantification of baseline or FICZ-induced AhR transcriptional activity 
without bias for specific gene targets. Day 30 HPs were transduced with AhR-driven reporter 
lentivirus or mock infected at a multiplicity of infection (MOI) of 10 and grown in basal medium 
containing 0.2 µM FICZ for 72 hours.  HPs were then subjected to three different growth 
conditions in order to assess the activity of AhR in this cell population:  1) the steady state 
condition consisting of cells maintained in 0.2 µM FICZ, 2) exposure to an increased FICZ 
concentration of 0.4 µM, or 3) growth in 0.2 µM FICZ but also in the presence of 5µM of a 
known AhR inhibitor, CH223191236.  In contrast to the mock-infected HPs, the AhR-driven 
reporter-infected HPs displayed a modest increase in dsRed expression suggesting that the AhR 
responsive elements (AhREs) in the reporter were being transactivated in the HPs (Figure 2.9B).  
An increase in the FICZ concentration to 0.4 µM significantly increased DsRed expression 
(Figure 2.9B).  These results are consistent with the induction of CYP1B1 expression in primary 
HPs after FICZ exposure (Figure 2.7B). Importantly, a significant decrease in DsRed expression 
(below the level of expression in the mock-infected populations) was noted when the reporter 
virus-infected cells, maintained in a basal level of 0.2 µM FICZ, were treated with 5 µM of 
CH223191 (Figure 2.9B).  Similar results were obtained using a lentivirus encoding an AhR-
driven luciferase or green-fluorescent reporter (data not shown). These studies confirm the 
presence of a functional, FICZ-responsive AhR in human HPs.  
 
 
 
  
50 
 
Figure 2.7. AhR agonist induces CYP1B1 target gene expression in human iPSCs and HPs. 
(A) Western blot analysis for AhR and β-actin protein expression in iPSCs and HPs.  (B) qPCR 
data of iPSCs and Day 15 HPs with and without 0.2mm FICZ for 3 days. Expression is 
normalized to β-actin levels. Data is average of 3 independent experiments + SD. *P<.05, 
**P<.005. Results shown represent work done by J. Ubellacker and A. Parks (A) and B. Smith 
(B). 
 
 
Figure 2.8. iPSCs and hematopoietic progenitor cells are responsive to a spectrum of AhR 
agonists. (A) RT-PCR analysis of CYP1B1 in iPSC treated with TCDD or β-NF for 4 days. Data 
are averages of duplicate wells + SE and values are normalized to GAPDH. (B) RT-PCR analysis 
of CYP1B1 in HP treated with β-NF or FICZ.  Data are averages of two independent experiments 
+ SE and values normalized to GAPDH. Results shown represent work done by J. Ubellacker and 
A. Parks. 
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In order to determine if FICZ-mediated transactivation of the AhR receptor was responsible for 
the exponential expansion of iPSC-derived HPs, the effect of AhR inhibition with CH223191 on 
cell viability and expansion of the HP population was tested. As previously shown in Figure 2, 
addition of 0.2 µM FICZ on day 7 of iPSC culture significantly increased the percentage of cells 
captured in the viable cell gate, as defined by forward and side scatter parameters (e.g., 15.5% vs. 
8.09%) (Figure 2.9C).  However, treatment with 5 µM CH223191 one day prior to addition of 
FICZ completely blocked the increase in viable cells as measured either by forward and side 
scatter parameters or propidium iodide uptake. Furthermore, no significant expansion of HPs was 
seen in cultures treated with CH223191 plus FICZ (data not shown). These data indicate that AhR 
activation with FICZ mediates an increase in HP viability and drives expansion of HP 
populations. The efficacy of the CH223191 was confirmed by its ability to block CYP1B1 
induction as assayed by qRT-PCR (Figure 2.9D).  
Chronic AhR activation is permissive to erythroid cell maturation  
Previous studies suggest that the AhR may play a critical role in hematopoietic cell development 
and function, possibly including the growth and differentiation of hematopoietic stem cells160,189–
191. Having shown that AhR activation results in exponential expansion of HP populations 
(Figure 2.6), and that the presence of EPO or TPO and FICZ generates either erythroid-lineage or 
Mk-lineage cells in the short term (Figure 2.4D), we then were in a position to determine if the 
AhR also contributes to HP differentiation into Mk- or erythroid-lineage cells over longer periods 
of time. To this end, HPs were cultured for extended periods of time (>120 days) in the presence 
of basal  
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Figure 2.9. AhR mediates the expansion and specification of hematopoietic progenitor cells. 
(A) Schematic representation of pHAGE2 lentiviral reporter constructs that contain the mouse 
mammary tumor virus flanking the dioxin response element (MMTV-DRE-MMTV) driving the 
expression of NLS-dsRed (pHAGE2-MMTV-DRE-MMTV-NLS-dsRed-IRES-zsGreen) (B) 
Representative FACS analysis for DRE-dsRED in HPs infected with pHAGE2-MMTV-DRE-
MMTV-NLS-dsRed-IRES-ZsGreen.  Infected cells were untreated or treated with 5µM 
CH223191, or 0.4µM FICZ.  (C) Representative flow cytometry dot plots of live versus dead 
cells (PI vs. Hoechst) from D15 HPs + FICZ and/or CH223191. For these experiments, HPs were 
pretreated with the known AhR inhibitor CH223191 at D6 before the addition of FICZ at D7. (D) 
Graphical representation of experiments performed in "C". For the live cell gate, data is the 
average of 3 independent experiments + SD: *P<.005; for the apoptotic cell gate, data is the 
average of 3 independent experiments + SD: *P<.04. (E) Expression of CYP1B1 as detected by 
qPCR of MEPs from “C”. normalized to β-actin. Data is the average of three independent 
experiments + SD. *P<.005. Results shown represent work done by G. Murphy (B), A. Leung (A, 
B, C) and B. Smith (E) and S. Rozelle (B, E).  
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medium containing 0.2mM FICZ. Immunophenotyping of cell cultures maintained in these 
feeder-free conditions over a 60-day period revealed a progressive erythroid specification and 
maturation.  As demonstrated in Figure 2.10A, the majority of early passage (Day 13) iPSC-
derived HPs expressed CD71 (transferrin receptor) with a portion of the cells also expressing 
CD235 (glycophorin A) suggesting an immature erythroid cell phenotype. Under prolonged 
exposure to FICZ (30 days), these cells begin to downregulate CD71 and a larger percentage of 
cells express CD235 suggesting a more mature phenotype (Figure 2.10A). By day 60 most 
(~70%) of the cells are CD235+/CD41- indicating specification to the erythroid lineage under our 
basal growth conditions (Figure 2.10B).  These populations of iPSC-derived erythroid-lineage 
cells demonstrate functional maturity as assessed by their ability to respond to hypoxia (Figure 
2.10C).  For example, when cultured under low oxygen concentrations (5% O2) to simulate stress 
erythropoiesis, cells display hallmark characteristics of maturing erythroblasts including a 
reduction in cell size and the condensation of chromatin within the nuclei of the cells (Figure 
2.10C).  More strikingly, when cells are centrifuged, bright red pellets can be seen indicating the 
production of hemoglobin (Figure 2.10D). In contrast to peripheral blood cells, which only 
express α-globin and β-globin (forming the most common form of hemoglobin in adult humans), 
iPSC-derived erythroid-lineage cells express α-globin, γ-globin (fetal), as well as two embryonic 
globins (ζ- and ε-globin) as judged by mass spectrometry analysis (Figure 2.11).  These results, 
as well as the lack of adult β-globin in this population suggest that iPSC-derived erythroid-
lineage cells are at an embryonic/fetal developmental stage.    
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Figure 2.10. Continuous AhR activation is permissive to erythroid cell maturation. (A) 
Representative FACS analysis of cells co-expressing two hallmark markers of the erythroid 
lineage: CD71-FITC (transferrin receptor, early) and CD235-PE (glycophorin a, late) at days 15 
and 30 of specification.  (B) Representative FACS analysis of cells co-expressing CD235-PE and 
CD41-FITC demonstrating that by day 60, virtually all of the cells are committed to the erythroid 
lineage. (C) Wright-Giemsa staining of D30 erythroid-lineage cells pre- and post-exposure to 
hypoxic conditions demonstrating decreased size and condensed chromatin under low oxygen 
conditions. (D) Hemoglobin expressing cell pellet of iPSC-derived erythroid-lineage cells. 
Results shown represent work done by S. Rozelle. 
  
 
 
  
55 
 
  
Figure 2.11. iPSC-derived erythroid-lineage cells express a spectrum of embryonic and fetal 
globins. (A) Mass Spectrometry analysis of human peripheral blood in comparison to D30 iPSC-
derived erythroid-lineage cells.  In contrast to peripheral blood cells, which only express a-globin 
and b-globin (forming the most common form of hemoglobin in adult humans), iPSC-derived 
erythroid-lineage cells express α-globin, γ-globin (fetal), as well as two embryonic globins (ζ- 
and eε-globin).  These results, as well as the lack of adult globin (β-globin) in this population 
suggest that iPSC-derived erythroid-lineage cells are at an embryonic/fetal developmental stage.  
Results shown represent work done by S. Rozelle and analyzed by R. Théberge. 
 
AhR repression promotes megakaryocyte specification  
As the default pathway in our system seemed to allow for the specification and maturation of 
iPSC-derived HPs into the red cell lineage under chronic AhR agonism, we hypothesized that 
AhR downregulation in these long-term cultures might allow for the emergence of the alternative 
lineage, megakaryocytes. To test this hypothesis, we evaluated the effects of AhR inhibition with 
ectopic expression of an AhR reporter plasmid previously shown to block human AhR 
transcriptional activity237,238. We constructed and utilized a lentiviral vector that encoded an AhR 
 
 
  
56 
repressor element (AhRR) along with a ZsGreen reporter (Figure 2.12A). This AhRR element 
potently and specifically inhibits either baseline or AhR agonist-induced AhR transcriptional 
activity237,238. In contrast to cells transduced with a control ZsGreen reporter, cells infected with 
the AhRR-ZsGreen lentivirus and cultured for 5 days produce a significantly higher number of 
large, CD41+ Mk-lineage cells (Figure 2.12C&D). Interestingly, while the AhRR-transduced 
populations were capable of producing Mk-lineage cells, they also contained fewer CD235+ cells, 
suggesting that AhR antagonism initiates a transcriptional switch from erythroid to 
megakaryocyte lineage specification (Figure 2.12C).   
To further study the Mk-lineage cells produced via AhR antagonism, a discontinuous 
BSA gradient (0, 1.5, 3%) was used to isolate mature Mks from AhRR-ZsGreen-transduced 
populations.  In contrast to the ZsGreen-AhRR- population, the majority of the ZsGreen-AhRR+ 
population was positive for a combination of two hallmark Mk lineage markers, CD41a and 
CD42b (Figure 2.12D). These cells also demonstrated hallmark characteristics of mature Mks 
including lobular nuclei and membrane blebbing at the surface of the cells (Figure 2.13A) and 
the ability to endoreplicate to 8N and 16N (Figure 2.13B). Quantitative PCR analysis of these 
cells also revealed robust upregulation of a spectrum of Mk-related genes including GPV, GPIIb, 
PF4, and CD62P (Figure 2.13C).  Functionality of iPSC-derived Mks was assessed by their 
ability to produce platelets. Mature Mks were grown on an OP9 stromal layer for 3-5 days to 
allow for terminal Mk differentiation and platelet production.   
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Figure 2.12. AhR repression promotes megakaryocyte specification. (A) Schematic 
representation of a pHAGE2 lentiviral reporter construct containing the AhR repressor (AHRR) 
and ZsGreen under the control of the constitutive promoter Ef1α (pHAGE2-Ef1α-AHRR-IRES-
ZsGreen). (B) Phase and fluorescent images of D30 HPs following infection with a constitutively 
active ZsGreen control virus or pHAGE2-Ef1α-AHRR-IRES-ZsGreen. Large cells 
(megakaryocytes) are noted in the populations infected with the AHRR.  (C) Graphical 
representation of the percentage of ZsGreen+ cells that express CD235 (erythroid lineage) or 
CD41 (Mk lineage) following mock or AhRR infection. Data are presented as means of three 
independent experiments + SD. *P<.005.  (D) FACS analysis of AhRR-ZsGreen negative vs. 
positive fractions for hallmark megakaryocyte markers CD41a/CD42b. Results shown represent 
work done by G. Murphy and B. Smith. 
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Figure 2.13. Characterization and functional analyses of iPSC-derived Mk-lineage cells. (A) 
Wright-Giemsa stain of megakaryocytes produced via AhR antagonism. (B) Ploidy analysis of 
iPSC-derived megakaryocytes demonstrating endoreplication. (C) qPCR analysis comparing 
undifferentiated iPSCs and iPSC-derived Mks for a spectrum of Mk-specific markers. Expression 
is normalized to β-actin levels. Data is average of 3 independent experiments + SD.  (D) FACS 
analysis comparing platelets in whole blood to iPSC Mk-derived platelets.  Mature Mks were 
grown on an OP9 stromal layer for 3-5 days to allow for terminal Mk differentiation and platelet 
production.  Cultures were initially gated using GPIIb (CD41a) expression and demonstrated that 
iPSC Mk-derived platelets were similar to platelet populations from whole blood with respect to 
size (FSC), granularity (SSC), as well as the expression of GPIX and GP1b, two subunits of the 
GPIb/V/IX complex, that are characteristic of platelets. Results shown represent work done by B. 
Smith.  
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Cultures were initially gated using GPIIb (CD41a) expression and demonstrated that iPSC Mk-
derived platelets were similar to platelet populations from whole blood with respect to size (FSC), 
granularity (SSC), as well as the expression of GPIX and GP1b, two subunits of the GPIb/V/IX 
complex, which are characteristic of platelets (Figure 2.13D). 
 
AhR agonism promotes HP production and expansion in murine bone marrow 
To determine if AhR agonism would result in HP production and expansion from bone marrow 
precursors in a murine system, red cell-depleted, bone marrow from C57BL/6 mice was cultured 
for 3 days in the presence or absence of vehicle or 0.2 mM FICZ.  Remarkably, in contrast to 
vehicle-treated controls, distinct populations of primary, Ter119+ erythroid-lineage cells and 
CD41+/Ter119+ HPs were noted in the cultures following just 3 days of FICZ treatment (Figure 
2.14A). Interestingly, a statistically significant decrease in cKit+ progenitor cells was noted in 
FICZ treated populations along with highly statistically significant increases in erythroid-lineage 
cells and HPs (Figure 2.14B).   
 
The AhR agonist FICZ is active in vivo and results in increased platelet counts in normal mice 
It is possible that FICZ, a photo-metabolite of tryptophan, plays a role in regulating 
hematopoiesis in vivo. To determine if FICZ treatment on whole animals would affect  
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Figure 2.14. AhR agonism decreases c-kit expression in murine MEPs. (A) Representative 
FACS analysis of red cell depleted C57B6 bone marrow grown for 3 days under basal murine 
growth conditions +/- 0.2 mM FICZ.  1 x 10^5 cells were initially treated with CD16/32 Fc 
receptor block, followed by a directly conjugated monoclonal antibodies for cKit.  (B) Graphical 
interpretation of FACS analysis for cKit (p=0.009) with or without the addition of 0.2 mM 
FICZ.  Results are representative of three independent experiments + SD.  Results shown 
represent work done by G. Murphy.  
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RBC or platelet production, C57Bl6 mice were injected daily intraperitoneally with FICZ 
suspended in vegetable oil using a weekly dose escalation scheme (Week 1: 1mg/kg; Week 2:  
2mg/kg; Week 3: 4mg/kg).  In contrast to mock-injected mice or mice injected with vehicle only, 
mice injected with FICZ showed increased platelet counts, as assayed by Hemavet quantification 
of peripheral blood bleeds, at all 3 time points (Day 7, 14, and 21) (Figure 2.15A).  Interestingly, 
a mouse that was immediately exposed to higher doses of FICZ (4 mg/kg) and did not undergo 
week 1 escalation demonstrated a more immediate and prolific platelet response.  None of the 
mice in the study showed significant variations in either white blood cell (WBC) or red blood cell 
(RBC) counts (not shown).  Following the 3-week time point, mice were sacrificed and livers and 
spleens harvested. Quantitative RT-PCR analyses for CYP1B1 target gene expression revealed 
robust upregulation in the liver and spleen of FICZ treated animals confirming that we had 
reached biologically meaningful FICZ doses in vivo (Figure 2.15). While agonism in an in vitro 
system promotes erythroid cells development, in vivo, AhR may interact with other factors 
affecting different signaling pathways than in vivo, allowing for an increase in platelets instead. 
Collectively, the in vitro data suggest that production of erythroid-lineage cells is the 
default in vitro pathway of HPs chronically stimulated with an AhR ligand. Inhibition of that 
default pathway results in an increase in the percentage of Mk-lineage cells, an outcome that 
could reflect either a switch in cell fate decision to favor Mk production or the maintenance of a 
small population of Mks during a decrease in the production of AhR-dependent erythroid-lineage 
cells (Figure 2.16). 
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Figure 2.15. The AhR agonist FICZ is active in vivo and increases platelet counts in normal 
mice. (A) C57B6 mice were injected daily intraperitoneally with FICZ suspended in vegetable oil 
at a dosage of 4mg/kg. In contrast to mock-injected mice or mice injected with vehicle only, mice 
injected with FICZ showed increased platelet counts, as assayed by Hemavet quantification of 
peripheral blood bleeds, with statistically significant increases seen at days 14 (P=.002), 17 
(P=.02), and 21 (P=.01) (B) Bone marrow from all mice was harvested at day 21, and following 
red blood cell depletion, samples were analyzed for viability (via propidium iodine staining) and 
immunophenotyped. In contrast to vehicle treated mice, the bone marrow cells of FICZ treated 
mice displayed a statistically significant increase in cell viability (P=.03) (C) Representative 
immunophenotyping of the bone marrow of all mice using a panel of hematopoietic markers 
revealing no noticeable differences between FICZ treated mice and vehicle treated controls.  (D) 
Livers were harvested from sacrificed mice to confirm AhR activity in vivo. Quantitative RT-
PCR analyses for CYP1B1 target gene expression normalized to GAPDH revealed robust 
upregulation in the livers of FICZ treated animals. Results shown represent work done by G. 
Murphy and S. Rozelle. 
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Discussion 
Our results suggest that that AhR has a physiological and functional role in normal hematopoietic 
development, and that modulation of the receptor in bipotential hematopoietic progenitors can 
direct cell fate.  We demonstrate a novel methodology for the directed differentiation of 
pluripotent stem cells in serum and feeder-free defined culture conditions into HPs capable of 
final specification into Mk- and/or erythroid-lineage cells.  
As a starting point for these studies, we utilized human hematopoietic cell differentiation 
genomic (dMap) array data as a roadmap for assessing the possible role of AhR in hematopoietic 
cells.  These analyses suggested that the AhR plays an important role in blood cell development 
and were consistent with previous studies160,221,224,239.  
 In our studies, we have found that the use of a non-toxic aryl hydrocarbon receptor 
agonist in a directed differentiation scheme dramatically increases the number of HPs and 
resultant cells.  This is an important finding in that traditionally, the evolutionarily conserved 
AhR has been studied for its role in environmental chemical-induced toxicity, and in our system it 
is shown to be involved in the growth and the differentiation of at least two crucial blood cell 
types.  Following the addition of the potent AhR ligand FICZ to our cultures, we observed 
exponential expansion of HPs from a few thousand to 100 million cells in fewer than two weeks. 
Importantly, the role of AhR in the HP population was confirmed using a highly specific AhR 
inhibitor. This logarithmic expansion of cells appears to be a function of decreased cell death and 
is consistent with previous studies which suggest that the AhR can control apoptosis211–213.  
It is important to note that these results can be contrasted with work performed by 
Gasciewicz et al. in which AhR activation leads to exhaustion of the HSC pool as opposed to 
hematopoietic cell expansion.  This apparent contradiction could reflect different stages in 
hematopoiesis (HSCs vs. HPs) or the nature of the ligand.  Interestingly, while the exposure of 
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murine bone marrow to AhR agonism resulted in increased numbers of erythroid-lineage cells 
and HPs, a decrease in cKit+ progenitor cells was also noted perhaps suggesting a preferential 
switch to bipotential progenitor fate. Considerable evidence also indicates that functional 
outcomes may differ when using different AhR ligands, for example TCDD vs. FICZ208.  
Interestingly, FICZ, the AhR ligand utilized throughout this work, is a photo-metabolite 
of tryptophan originally described by the Rannugs240.  Based on previous 
 
Figure 2.16. Mechanistic diagram of AhR involvement in normal hematopoietic 
development. The AhR agonist FICZ allows for the production and exponential expansion of 
hematopoietic progenitor cells (HPs).  Continued AhR agonism is permissive to erythroid-lineage 
cell maturation whereas AhR antagonism elicits a transcriptional switch, which preferentially 
directs HPs to become megakaryocytes. 
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studies demonstrating the ubiquity of FICZ241 and taken together with our data demonstrating the 
activity of this ligand, it is possible that FICZ plays a role in regulating hematopoiesis in vivo, 
possibly with other endogenous AhR ligands. In our in vitro system this leads to the expansion of 
erythroid lineage cells. In vivo, FICZ’s interactions with other AhR ligands may explain the 
increase in platelets seen in mice injected with FICZ. The ability to expand HPs in vitro with an 
AhR ligand also suggests that blood cell development may be affected by a variety of 
environmental ligands224,242. 
In addition to allowing for the exponential expansion of HPs, our results indicate that 
AhR modulation is also involved in the further specification of both the erythroid and Mk 
lineages with AhR agonism permissive to the differentiation of erythroblasts and antagonism or 
downregulation of AhR leading to Mk specification. Although erythropoietin (EPO) and 
thrombopoietin (TPO) are the major drivers in RBC and platelet development, AhR may play a 
cytokine-independent role in the development and specification of these lineages and warrants 
further study in this capacity.   
During the course of our studies, we derived putative progenitors known to express 
markers of both the Mk and erythroid lineages. A particularly striking outcome of our 
experiments is the development of a simple protocol for the rapid and highly efficient derivation 
of putative HPs, which expand exponentially under AhR agonism. In addition to the ability to 
answer basic biological questions concerning hematopoietic development, a useful outcome for 
this work will be the utilization of this in vitro platform for the production of blood products as 
the combination of AhR modulation with a completely chemically defined and xenobiotic agent-
free differentiation scheme makes good manufacturing practice production and clinical translation 
feasible. Blood transfusion is an indispensable cell therapy, and the safety and adequacy of the 
blood supply are of national and international concern. An iPSC-based system, such as the one 
 
 
  
66 
described here in which large numbers of cells can be produced, could allow for red blood cell 
and platelet transfusion without problems related to immunogenicity, contamination, or supply.  
Furthermore, the ability to produce both populations of cells from a single source, and the fact 
that both platelets and mature RBCs contain no nuclear genetic material decreases safety 
concerns with the use of iPSC-derived cells and paves the way for clinical translation.   
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CHAPTER 3: 
IN VITRO AND IN VIVO MODELS OF ERYTHROPOIESIS 
 
Introduction 
Erythropoiesis: from HSC to erythrocyte  
Erythrocytes, or red blood cells (RBCs), can be classified as primitive or definitive depending on 
the origin of the cell. Primitive erythropoiesis occurs early in embryonic and fetal development in 
the yolk sac. Primitive RBCs, while very similar to definitive RBCs, can complete their 
maturation, including enucleation, in the bloodstream, but express a panel of embryonic and fetal 
hemoglobins7. When hematopoiesis moves to the bone marrow, all definitive hematopoietic cells 
are produced from the hematopoietic stem cell (HSC). Erythropoiesis from the HSC requires a 
series of cell fate decisions that rely on transcription factor expression to direct which type of 
mature hematopoietic cell a progenitor will become. Daughter cells of the HSC undergo 
specification to the common myeloid progenitor and then towards the megakaryocyte erythroid 
progenitor (MEP) due in part to upregulation of GATA1, in contrast to the persistent signaling 
from PU.1 in the lymphoid pathway38,243–245. The MEP, a short-lived progenitor, receives the last 
signals required for erythroid specification from erythropoietin and the upregulation of erythroid 
specific transcription factors246. The final stages of erythroid differentiation involve maturation 
steps, which alter morphology and cell surface markers, and increases hemoglobin production 
(Figure 3.1). 
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Figure 3.1 Erythroid development takes place in the bone marrow through a series of 
intermediate cell types. Adapted from http://nephrotube-anemia-
ckd.blogspot.com/p/erythropoiesis-rbcs-formation.html 
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Erythropoiesis: Morphological changes during maturation 
Under normal levels of EPO, RBCs develop within weeks progressing through multiple steps of 
maturation. The individual cell types are characterized morphologically based on size, 
hemoglobin content, and the size and appearance of the nucleus. The first erythroid specific 
precursor produced under EPO stimulation is the pro-erythroblast, which has a large nucleus and 
limited hemoglobin in the large cytoplasm247. The basophilic erythroblast contains a slightly 
smaller nucleus and is more basophilic than the pro-erythroblast due the ribosome content in the 
cytoplasm as hemoglobin production escalates. The last erythroid lineage cell capable of mitosis 
is the polychromatophilic erythroblast. The cytoplasm of polychromatophilic erythroblasts stains 
more grey than blue, as the increased amounts of hemoglobin in the cytoplasm are more 
acidophilic. The normoblast is the smallest nucleate cell in the erythroid lineage. The chromatin 
in the nucleus has condensed, showing up as a very dark compact structure. After the nucleus is 
extruded, the cell is known as a reticulocyte. Nuclear extrusion, or the process of expelling the 
nucleus from the cell, takes place in erythroblastic islands consisting of a central macrophage 
surrounded with differentiating and enucleating erythroblasts within the bone marrow63–65. Upon 
signals from the macrophage, an RBC releases its nucleus, which is promptly phagocytosed by 
the macrophage, leaving an anuclear cell behind. Even after nuclear extrusion there is sufficient 
mRNA to continue hemoglobin production for 1-3 days. Within 24 hours of reticulocytes 
escaping into the circulation, the cells take on their characteristic biconcave shape due to 
membrane loss and remodeling that allows RBCs to have increased surface area for optimal 
oxygen exchange and the deformability to navigate the fine vascular structures of the 
microcirculation66 (Figure 3.2).  
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Figure 3.2. Morphology and surface markers of erythroid maturation. Maturation of 
erythroid cells can be visualized by size, morphology, as well as color, from stains such as 
Wright-Giemsa. During the erythroblast stages the cell is accumulating hemoglobin and reducing 
other proteins in the cytoplasm followed by condensation of the chromatin and exclusion of the 
nucleus. Once in circulation the cell will become a biconcave disc. Modified from Marieb and 
Hoehn248. 
 
  
 
 
  
71 
Erythropoiesis: Cell surface markers identify RBC maturation state 
The most commonly used cell surface markers used for identification of erythroid lineage cells 
are glycophorin A and the transferrin receptor. Glycophorin A, also known as human CD235a, or 
its counterpart, murine Ter119, is expressed on the cell surface of hematopoietic cells with 
erythroid potential249,250. It is expressed ubiquitously throughout erythroid development with 
similar levels on pro-erythroblasts and erythrocytes251,252. And while it is useful for locating 
erythroid cells, its constitutive expression makes it unable to discern maturation differences. The 
transferrin receptor, CD71, in conjunction with CD235a can to identify specific stages of 
erythroid development253–255. CD71 is required early in erythroid development for the uptake of 
transferrin, and thus allows for the transport of iron needed for hemoglobin production256,257. 
Reduction in hemoglobin synthesis and removal of non-essential proteins during the final stages 
of maturation results in loss of CD71 expression 251,252,258. Complete loss of CD71 occurs at the 
reticulocyte stage allowing reticulocytes to be identified as anuclear cells with 
CD235a+CD71low/neg surface markers (Figure 3.2). 
 
Hemoglobin Expression: A site-specific oscillation through development 
Hemoglobin expression, while dependent on erythropoiesis, is not regulated by erythroid 
maturation. The site of hematopoiesis plays a larger role in the regulation of which hemoglobin 
molecules are expressed, rather than the maturation state of the cells. This is due to the variety of 
transcription factors involved in hemoglobin expression and their time/site specific expression. 
 Human hemoglobin, made up of a dimer of dimers has 6 distinct normal variants.   
During early human embryonic development the embryo relies on the yolk sac for nutrients. It is 
here, in the yolk sac blood islands, that that the first primitive RBCs are derived7,61. These early 
RBCs express embryonic globins zeta (HBZ) and epsilon (HBE). These hemoglobins have been  
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Figure 3.3 Hemoglobin expression varies as a result of the site of hematopoiesis.  
Hemoglobin expression changes as the site of hematopoiesis moves from the yolk sac to the bone 
marrow. This results in down regulation of embryonic (ε) and fetal (γ) and upregulation of beta 
(β), while alpha (α) is expressed throughout. Modeled after Sankaran and Nathan58. 
 
 
found to make up a variety of tetramers including ζ2ε2 (Gower1), small amounts of α2ε2 (Gower2) 
and ζ2γ2 (Portland1). As the embryo develops, the site of hematopoiesis moves from the yolk sac 
to the aorta-gonad-mesonephros (AGM) region and then to the fetal liver. This allows for the 
increase in the number of hematopoietic cells required to support the growing fetus. RBCs in the 
fetal liver produce alpha (HBA2 and HBA1) and gamma (HBG2 and HBG1) globins to make fetal 
hemoglobin: α2γ2 (HbF). HbF is required at this stage of development when fetus is taking 
oxygen from the mother62. HbF has higher oxygen binding affinity, allowing for oxygen to be 
removed from the maternal blood system and transported to the fetus259. Towards the mid stages 
of gestation, hematopoiesis moves to the bone marrow, where it will reside for the adult life of 
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the individual. The HSC, which resides in the bone marrow, is the source of all definitive 
hematopoiesis. Commonly referred to as hemoglobin switching, this time only the gamma chain, 
expression is downregulated, switching to high expression of beta globin, HBB. This final form of 
hemoglobin, α2β2 or HbA, makes up 97-99% of the hemoglobin expressed in the adult with <1% 
HbF62 (Figure 3.3). 
 
Mouse Models for the study of in vivo hematopoiesis 
The in vitro study of human erythropoiesis is extremely difficult and humanized mice have aided 
this quest. Humanized mice have been injected with human cells for the study of cellular 
potential, maturation, and hemoglobin switching. This is a common method for observing bone 
marrow reconstitution 260,261, defects in hematopoiesis262,263, HSC and progenitor cell 
potential11,160,264,265, progenitors from iPSC sources266 and erythropoiesis267. 
Humanizing a mouse, in which the human cells are the sole focus, requires the removal 
or depletion of the murine component and the addition of human cells as the replacement268. To 
maintain these cells for study the mice must be altered by compromising their immune system 
Nod-SCID (NOD.CB17-Prkdcscid/J) mice are one example of an immunocompromised mouse269–
271. However, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice are more receptive to human cells 
than their Nod-SCID counterparts due to the deletion of IL2Rgamma 272–276. To increase 
dependence on the human hematopoietic cells NSG mice can be sub-lethally irradiated182. This 
will cause apoptosis in murine hematopoietic cells in the mouse. When human cells are injected 
into the mice, they replace the cells that are lost, creating an environment in which the mouse is 
dependent on the human cells. Human hematopoietic cells can reconstitute the mouse with 
continued production of all hematopoietic lineages for months182,272,273,277. The advancements in 
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humanized mouse models offer stem cell biologists valuable tools to study the development and 
differentiation of cells created in vitro in an in vivo environment. 
 
Materials and Methods 
Cell generation and culture: Hematopoietic progenitors (HP) were generated from iPSCs using 
our previously published protocol278. Cells were kept in D7 media unless otherwise noted, 74% 
IMDM, 24% Hams F12, 1% B27 supplement, 0.5% N2-supplement, 0.5% BSA, 50ng/ml 
hVEGF, 100ng/ml bFGF, 100ng/ml hSCF, 25ng/ml hFlt3 Ligand, 50ng/ml hTPO (Genentech 
G140BT), 10ng/ml IL-6 (R&D 206-IL-010), 0.5U/ml hEPOgen (Amgen) and 0.2 µM 6-
formylindolo[3,2-b]carbazole (FICZ) (Santa Cruz SC300019). Mitomyocin-C treated OP9 
stromal layer was plated on gelatin coated well in DMEM, FBS, 2mM L-Glutamine (Invitrogen 
25030081), and 100 mg/ml Primocin. 
 
Staining: Cells were cytospun onto glass slides and stained with either Wright-Giemsa or 
Benzidine stains. Wright-Giemsa stains were performed with the Hema 3 Stat Pack (Fisher 23-
123869). Benzidine stains were performed using DAB Peroxidase Substrate Kit, 3,3’-
diaminobenzidine (Vector Labs SK-4100) according to manufactures instructions. Slides were 
imaged on a Nikon Eclipse Ti and images processed and quantified with ImageJ software. 
 
Sorting and Microarray: HPs on day 15 and day 30 that were non-adherent cells were collected, 
washed into PBS-0.5% BSA, and stained for 45 minutes on ice with human CD235a-FITC (BD 
559943). Cells were washed and resuspended in PBS-0.5% BSA with 1 µg/mL Propidium Iodide. 
The Beckman Coulter MoFlo Legacy at Boston University’s Flow Cytometry Core Facility was 
used to collect 100,000-200,000 CD235+ cells. Following the sort cells were pelleted and 
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resuspended in 200 uL QIAzol Lysis Reagent (Qiagen 79306). RNA extraction of samples and 
running of the Illumina gene expression microarray was completed by the Baldwin Lab at Boston 
University and Paola Sebastiani of Boston University School of Public Health completed analysis 
of the microarray data in consultation with the Murphy Lab. 
 
Maturation media: Cells were washed and then grown as a non-adherent culture in either Day 7 
media or SFD (74% IMDM (Invitrogen 12330061), 24% Hams F12 (Mediatech 10-080-CV), 
0.5% N2 supplement (Invitrogen 17502-048), 1% B27 supplement (Invitrogen 12587-010), 0.5% 
BSA in PBS (Sigma A1470, Cohn analog)), 5% Plasmanate, 10-7M FICZ (Santa Cruz, 
SC300019-S, and 3U/mL hEPOgen, for 3 days. Cells grown in EMM1 were washed and then 
grown as a non-adherent culture in IMDM, 5% Plasmanate, 5% protein free hybridoma media II, 
PFHII (Life Technologies 12040-077), 2 U/mL hEPOgen (Amgen NDC55513-144-01) for 7-9 
days. Cells grown in EMM2 were washed and then grown as a non-adherent culture in IMDM, 
5% Plasmanate (Talecris Biotherapeutics Inc. NC27709), 5% PFHII, 2 U/mL hEPOgen, and 300 
ug/mL transferrin (Sigma T0665) for 9 days. All medias contained 2mM L-Glutamine (Invitrogen 
25030081), 4x10^-4 M Monothioglycerol (Sigma M1753), 50ug/ml Ascorbic Acid, and 100 
mg/ml Primocin.  
 
Humanized Mouse Models: Nude (J:NU Tyrc/Tyrc, Jax #007850) and NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ, Jax #005557) mice from Jackson Laboratories were housed in Boston 
University’s Animal Facility according to National Institutes of Health and Institutional 
guidelines for the care and use of animals in research. Mice were anesthetized and numbered 
using ear punches. Sub-lethal irradiation of 2.5 Gy 182 was performed under semi-sterile 
conditions using a cesium-137 source. Cells were washed into PBS+ and 7-10, 50 or 100 million 
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approximately day 30 erythroid lineage cells were injected intraperitoneally 24 hours post 
irradiation. Retro-orbital bleeds were performed into EDTA coated vials and peripheral blood 
used for FACS and luciferase analysis. 
 
Generation of lentivirus and infection of hematopoietic progenitors: The pHAGE2-Ef1α-
luciferase plasmid was a gift from the Wilson Lab. VSV-G pseudotyped lentivirus was packaged 
and concentrated as previously described. On day 20 HPs were infected with lentiviruses 
containing Ef1α-luciferase or Ef1α-ZsGreen at an MOI of 1 to 10 with the addition of polybrene 
(5 µg/ml) to D7 media. After 24 hours cells were pelleted and resuspended in fresh D7 media for 
expansion. 
 
In vivo imaging: Luciferase activity was detected with 200 µL of 30 mg/mL D-Luciferin 
Injection Ready Substrate (System Biosciences BLIV800A-1) per mouse or 200 µL of 30 mg/mL 
D-Luciferin in PBS (Perkin and Elmer 122796). Mice were imaged with a 3 min exposure on a 
Xenogen Spectrum In Vivo Imaging System 100 (IVIS) after 30 minutes incubation. Images were 
processed and signal quantified using Xenogen’s Living Image Acquisition/Analysis Software. 
Luciferase imaging for cells, peripheral blood, and spleen homogenates was performed in a 96-
well plate following a 2-minute incubation with 22.5 µg D-Luciferin.  
 
Flow cytometry: Roughly 10^5 cells were collected, spun, and re-suspended in 0.5% BSA in 
PBS. Samples were incubated for 30 min at ambient temperature with human antibodies 
including CD41a-FITC (BD 555466), CD235-PE (BD 555570), CD71-FITC (BD 555536), 
CD71-APC (BD 341028) washed and spun at 3300 rpm for 7 minutes, and re-suspended in 0.5% 
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BSA in PBS with 1 mg/ml Propidium Iodide. Samples were run on a BD FACScalibur using 
Cellquest Pro software and analyzed via FloJo 8.7.   
 
Results 
The in vitro modeling of erythropoiesis from stem cells is a difficult task. While many methods 
have been attempted they usually require cell purification step, co-culture with stromal layers, or 
technically difficult embryoid body formation233. Very few mature cells are produced and only 
two have demonstrated the production of cells with primarily HBB expression165,169. Given that 
our HP differentiation protocol (see chapter 2) robustly generates progenitors capable of 
erythroid specification, we hypothesized that these cells were capable of both erythroid 
maturation and switching, which will ultimately allow me to observe differences between 
wildtype and SCD-derived cells. 
 
Directed differentiation to HPs causes upregulation of erythroid specific genes. 
As cells specify to a particular lineage their gene expression changes. This results in an increase 
in lineage specific genes with a concordant decrease in other lineages. To test the ability of the 
iPSC-derived HPs to specify towards the erythroid lineage we conducted a microarray gene 
expression of sorted CD235+ cells in comparison to undifferentiated samples. This was done with 
sorted 100-200,000 day 15 and 30 cells and unsorted day 60 cells (Figure 3.4A). Day 60 was 
unsorted as at this time point 80% of the cells express CD235 (Figure 2.10). Three cells lines 
were used to examine differences between control and sickle cell disease-specific iPSC used in 
differentiations. There is no observable differences between the lines, indicating that sickle cell 
disease-specific iPSC have the same potential to upregulate erythroid lineage genes as wild type  
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Figure 3.4. Differential gene expression of undifferentiated cells and erythroid-lineage cells.  
A) Sorting of D15 and D30 cells was done by FSC vs. SSC, propidium iodide for live cells and 
then for hCD235-FITC+. B) Differentially expressed genes seen between undifferentiated 
(undiff) and day 15 cells with Illumina microarray. Results shown represent work done by S. 
Rozelle (A), Baldwin Lab and P. Sebastiani (B). 
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Figure 3.5. Clustering analysis for erythroid specific genes. Clustering analysis of erythroid 
specific genes comparing undifferentiated (undiff) and day 15 cells for control cells and two 
sickle disease specific lines. Results shown represent work done by S. Rozelle and the Baldwin 
Lab and analyzed by P. Sebastiani. 
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Figure 3.6. Graphical representation of pluripotency and erythroid specific gene expression 
during differentiation. Bar graphs showing log fold change for pluripotency (A) and erythroid 
specific (B) gene expression in undifferentiated (undiff), day 15, and day 30 cells from the 
microarray. Results shown represent work done by S. Rozelle and the Baldwin Lab and analyzed 
by S. Rozelle and P. Sebastiani. 
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control cells. Clustering demonstrates a large number of genes downregulated with differentiation 
with only a small subset upregulated (Figure 3.4B). Closer analysis of erythroid and pluripotency 
genes shows loss of pluripotency as the cells go through differentiation, and upon day 15, as a 
hematopoietic progenitor (HP) there is upregulation of erythroid specific genes (Figure 3.5). 
Graphical representation of gene expression over time of a subset of genes confirms shows 3 fold 
upregulation erythroid specification and 1.5 fold decrease in of pluripotency factors Oct4, Sox2, 
Nanog expression (Figure 3.6).  BCl11, a gene that plays a key role in silencing HBG expression 
is down regulated early in erythropoiesis and upregulated after hemoglobin switching. 
 
Maturation medias cause morphological and cell surface marker expression changes consistent 
with erythroid maturation. 
Historically, erythroid lineage cells are made to mature to the point of enucleation through co-
culturing and/or maturation medias233,279. The use of co-culturing eliminates the ability of the 
produced cells to be used clinically, as there is no guarantee cross-contamination will not occur. 
This is even more critical when the stromal layer utilized is murine instead of human. Therefore, 
is it important to create an environment in which the cells can mature in a chemically dependent 
manner. When cells persist in the HP production media, Day 7, they are capable of limited 
maturation as seen by CD235 and CD71 expression as well as the ability of the cells to respond to 
low oxygen conditions (Figure 2.10). This media is designed for the production of HPs, and 
therefore contains cytokines that signal for hematopoietic progenitor specification and 
proliferation. Removal of these cytokines allows further specification to the erythroid lineage. 
Plasmanate, a human plasma-mimetic, was used to mimic the environment in which erythroid 
cells are known to mature. Plasmanate contains albumin and globulins, and other normal blood 
proteins which aid in creating an environment conducive for RBC maturation280. A maturation 
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media using plasmanate demonstrates the ability of a heterogeneous HP population to increase 
CD235+ CD71+ from 54.6% to 72.7%. There is also an increase in CD235+ from 7.5% to 18.4%, 
suggesting these cells are capable of full maturation (Figure 3.7A). While this condition allow for 
surface marker changes, little to no changes in cellular size were noted (Figure 3.7B). To verify 
that the cells are capable of enucleation cells were cultured with an OP9 human bone marrow 
stromal layer. FACS results for CD235 and CD71 show that the presence of OP9s also allows for 
generation of a more homogenous population of cells. Co-culture with OP9s dramatically 
increased the number of solely CD235+ cells in Day 7 media. The number of CD235+ cells 
increases from 37.5% to 46.3% when the cells are cultured in a maturation media containing 
IMDM, 5% PFHMII, 5% Plasmanate, and 2 U/mL of EPO, also known as EMM1 (Figure 3.8). 
Serum-free protein free hybridoma media (PFHMII) was added to the maturation media to help 
support the cells in suspension culture179. Cells grown on OP9s in EMM1 enucleate in very small 
amounts, less than 1% (Figure 3.8, red arrow) While EMM1 is useful to mature HPs to 
enucleated erythroid cells, it is not sufficient for extended propagation of the cells off the OP9 
stromal layer. Additions to EMM1 including transferrin, ascorbic acid, and α-monothiol glycerol 
to create EMM2 were sufficient to generate a homogenous population of erythroid lineage cells 
with 35.2% CD235+ without a stromal layer (Figure 3.9). Cells cultured in EMM2 in a spin 
culture demonstrated more enucleation than static cultures (data not shown) and increased their 
hemoglobin content 1.5-5 fold depending on the cell line, as seen with benzidine staining 
(Figures 3.10 & 3.11).  
While erythroid cells capable of maturation and enucleation can be generated from 
human normal and sickle iPSCs, hemoglobin switching in vitro does not occur. To examine 
hemoglobin switching it we next turned to an in vivo model. 
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Chimerism of iPSC-derived erythroid cells in humanized NSG mice 
While limited maturation can be achieved, in vitro hemoglobin switching rarely occurs in the 
laboratory. In 2012, Kobari et al. demonstrated with HPLC that iPSC derived erythroid-lineage 
cells injected into NOD/SCID-LtSz-scid/scid (NSG) mice were capable of producing not only 
beta globin, but the sickle cell isoform as well182. While this study was promising there were so 
few RBCs produced that only HPLC analysis was performed. This study suggested that should 
large quantities of human erythroid lineage cells be used, hemoglobin switching might be 
observed. Accordingly NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), were sub-lethally 
irradiated with 2.5 Gγ and the following day 10, 50 or 100 million erythroid lineage cells were 
injected intraperitoneally. Both retro-orbital bleeds and bone marrow harvesting were performed 
to detect the presence of the human cells. CD235-FITC antibody separates human erythroid cells 
from murine erythroid cells allowing the detection of human cells in the bone marrow on Day 14 
as 34.6% of the total population (Figure 3.12B). One week later, on D21, 0.1% of the peripheral 
blood population was human cells (Figure 3.12C). As the spleen is a primary the site of 
hematopoiesis in the mouse, as well as the site of RBC destruction, histological sections were 
made from each mouse spleen. H&E staining revealed the presence of RBCs in the spleen in 
higher quantities than the control mouse (Figure 3.13). Interestingly, there appears to be more 
RBCs in the spleens of the mice who received 10 million cells from SCD-specific iPSC than the 
mouse who received 50 million control cells (Figure 3.13). Based on these results we 
hypothesize that the SCD-specific cells have matured to the point in which they have sickled and 
accumulated in the spleen awaiting destruction by splenic macrophages. 
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Figure 3.12. Human cells demonstrate chimerism in NSG-mouse model. A) Large scale 
production of HPs from WT iPSC for intraperitoneal injection into mice. B & C) FACS of human 
CD235 expression demonstrates chimerism in bone marrow after 14 days and peripheral blood 
after 21 days. D) Wright-Giemsa stain of Day 21 murine peripheral blood.  
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Figure 3.13. H&E stains of spleens from humanized NSG mice. Large amounts of RBCs 
accumulate in the spleens of humanized mice, more so when cells are derived from SCD-specific 
iPSC. 
 
 
Figure 3.14. HPs can be infected with luciferase expressing lentivirus. A) Model of vector 
with a constitutive promoter, Ef1α, driving luciferase expression. B) IVIS image of multiple cell 
lines infected with 100 uL of virus expressing luciferase.  
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In vivo visualization of human erythroid lineage cells in mice using constitutive luciferase 
expression 
To map the presence of the human cells in the mouse over time, erythroid lineage cells were 
infected with constitutively expressed luciferase (Figure 3.14). When the cells are exposed to 
exogenous D-luciferin the luciferase within the cells catalyzes a chemical reaction that results in 
the emission of light that can be detected at 560 nm on an In Vivo Imaging System (IVIS). 
Initially these experiments were done in Nude mice for optimal visualization of the cells. 8-10 
million cells infected with a lentivirus containing Ef1a-luciferase were injected intraperitoneally 
and anesthetized mice imaged every other day starting 24 hours after injection of the cells. Eight 
million FG293 cells were also infected with Ef1a-luciferase and injected into a mouse as a control 
for infectivity of the cells and location of the signal, as these cells are incapable entering the 
lymphatic system and ultimately the peripheral blood as seen with hematopoietic stem cell 
transplants. While the signal varies from day to day, it persists for 21 days (Figure 3.15). There 
appears to be foci of signal in the lower quadrants of the mice and some near the upper right 
quadrant, possibly in the spleen, suggesting that these cells are capable of homing to the bone 
marrow and entering the peripheral blood (Figures 3.16 & 3.17). Cells expressing Ef1a-
luciferase were put in maturation media for 9 days and the signal analyzed on the IVIS (Figure 
3.18). While nude mice are optimal for imaging purposes, they contain an intact immune system  
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Figure 3.15. Quantification of luciferase signal in region of interests denoted in Figures 3.16 
and 3.17. A) Line graph showing total counts x 104 for days 1-21. B) Line graph for days 3-21 
displaying total counts x 104. 
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Figure 3.16. IVIS luciferase images of days 1-11 of nude mice injected with 10 million 
human cells expressing luciferase. Cells appear as colored pixels in the mice with the color blue 
indicating low amounts of cells and red high amounts of cells. Red boxes indicate defined regions 
of interest used for quantification of the signal. Initial exposures were too short and a time course 
was done to determine 3 minutes the optimal exposure time. 
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Figure 3.17. IVIS luciferase images of nude mice injected with 10 million human cells 
expressing luciferase. A) Cell appears a colored pixels in images for days 13-21. Blue color 
indicates few cells, red many. B) Luciferase IVIS image of the BU5-B mouse spleen (left) and 
liver (left). 
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that can attack the human cells and reduce survival. Therefore it was important to return to using 
NSG mice. NSG mice were irradiated as before, 8-10 million cells infected with Ef1a-luciferase 
injected intraperitoneally, and anesthetized mice imaged every 3 days starting 24 hours after 
injection of the cells. Days 1-7 show high amounts of signal as the cells are near the surface of the 
mouse, but as the majority of the cells enter the lymphatic system and ultimately the peripheral 
blood the signal diminishes (Figures 3.19 & 3.20). Variation in signal intensity from day to day 
was thought to be due to variation in purchased D-luciferin batches used and therefore all 
subsequent experiments utilized the same batch of D-luciferin made in the laboratory. The signal 
in this experiment diminished much more quickly than previous experiments (Figure 3.20), 
which raised the question if these mice still had the capacity to remove the human cells from 
circulation. In NSG mice the remaining immune cell that could be clearing the human cells from 
circulation is the macrophage 272.  
 
Depletion of macrophages in humanized Nod-SCID Gamma (NSG) mouse model does not 
increase viability of mice or injected human erythroid cells 
Macrophage depletion can be obtained in a site-specific manner through the use of liposomal 
delivery of clodronate281. Clodronate, dichloromethylene diphosphonate CL2MDP, in the cytosol 
of cells can be mistakenly identified as a pyrophosphate and is used to generate an ATP analog. 
This non-hydrolyzable ATP analog can enter the mitochondria outer membrane and by 
irreversibly binding to ATP transporters disrupt the polarization of the mitochondrial membrane, 
leading to apoptosis282. As clodronate is toxic to cells, targeted delivery using liposomes, 
clodrosomes, allows for uptake by cells that phagocytosis foreign objects, mainly macrophages. 
While clodrosomes can be delivered directly to the site in which depletion is desired283,284, 
intraperitoneal injections has been demonstrated to target macrophages in the spleen, liver and  
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Figure 3.18. IVIS images of luciferase signal of cells in day 7 media or erythroid maturation 
media 1 for 7 days. Cells appear as colored pixels with the color blue indicating low amounts of 
signal and red high amounts of signal.  
 
 
 
peritoneum285,286. Previous experiments suggested that it takes five-seven days to fully deplete the 
macrophage population and therefore multiple treatments of clodrosomes were necessary287.  
Depletion of macrophages was attempted twice, under differing conditions, but with 
similar results. Initially, macrophages were depleted post- irradiation and injection of the 10 
million human cells expressing Ef1a-luciferase and Ef1a-ZsGreen (Figure 3.21A). ZsGreen was 
to be used as a method for identifying human cells without having to undergo a staining protocol, 
which could have resulted in variable results. Unfortunately, treatment with 200 µg of 
clodrosomes resulted in low viability for the treated mice and no conclusions regarding the 
persistence of the human cells could be made (Figure 21B). Analysis of the spleens by imaging 
or spleen homogenates with additional D-luciferin treatment revealed no luciferase or ZsGreen 
expression. This was also confirmed using a peripheral blood from retro-orbital bleeds (Figure 
3.22B). Due to the early death of the mice, the protocol was adjusted. 
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Figure 3.19. IVIS luciferase images of days 1-17 of humanized NSG mice with two luciferase 
expressing control cell lines BU5 and BU6. Cells appear as colored pixels in the mice with the 
color blue indicating low amounts of cells and red high amounts of cells. Red boxes indicate 
defined regions of interest used for quantification of the signal. 
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Figure 3.20. Quantification of luciferase signal in region of interests denoted in figure 3.19. 
A) Line graph showing total counts x 104 for days 3-19 of individual mice. B) Line graph for 
days 3-21 displaying the average total counts x 104 per treatment group. 
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Macrophage depletion with a lower concentration of clodronate, 100 µg, began prior to 
irradiation, under the assumption that there would be better human cell survival and bone marrow 
reconstitution if there were fewer macrophages present when the human cells were initially 
injected into the mice (Figure 3.23A). This experiment also limited the handling and 
anesthetizing of the mice by combining the injections of clodrosomes to the days in which the 
mice were imaged. Unfortunately there was no improvement in mouse viability following this 
protocol and conclusions about human cell viability could not be made (Figures 3.23B & C). 
While this method of macrophage depletion is robust, others have also noted that these 
experiments required an increased number of mice, compared to traditional experiments, to 
account for the premature death of the mice287.  
Discussion 
Erythropoiesis has been studied extensively in xenopus, zebrafish, rats, chickens, mice, and 
humans. Yet with all we understand about the process of making RBCs, to do so efficiently in 
vitro has eluded researchers for years. An even more difficult process is making RBCs that have 
matured to produce enucleated RBCs with expression of HbA. Researchers have invested years 
trying to make this a reality233. By using erythroid progenitors derived from iPSCs large numbers 
of cells can be obtained for studies into the steps of maturation and hemoglobin switching. With 
our method of producing HPs millions of cells to test maturation and in vivo models could be 
obtained. 
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Figure 3.21. Clodronate treatment of humanized NSG mice. A) Experimental diagram 
indication time points for either empty or 200-µg clodronate filled liposome injections. B) IVIS 
luciferase images of mice that received nothing, empty liposomes, or clodronate liposomes with 
and without cells. Cells appear as colored pixels in the mice with the color blue indicating low 
amounts of cells and red high amounts of cells. Red boxes indicate defined regions of interest 
used for quantification of the signal. 
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Figure 3.22. Analysis of luciferase signal. A) Line graph displaying the average total counts x 
104 per treatment group for days 3-9 B) IVIS image of luciferase expression in peripheral blood 
or spleen homogenates from mice 1, vehicle, and 2, cells. 
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Figure 3.23. Humanized NSG mice treated with 100 µg of clodrosomes. A) Experimental 
diagram indication time points for liposome injections. B) IVIS luciferase images of mice that 
received nothing, empty liposomes, or clodronate liposomes with and without cells. C) Line 
graph of average luciferase counts x 104 per treatment group. 
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 Erythroid maturation occurs most reliably on stromal layers such as murine fetal liver or 
human bone marrow stroma, OP9. Co-culturing creates opportunities for contamination of the 
produced cells, limiting their clinical applications. I set out to demonstrate that our cells are 
capable of maturation, and then to do so in a chemically defined manner. The microarray data 
verified that our differentiation protocol to HPs create a transcriptional environment conducive to 
the maturation of erythroid lineage cells (Figures 3.5 & 3.6). It also showed that crucial erythroid 
lineage and hemoglobin regulators such as KLF1 and BCLl11A were regulated as expected.  
Limited maturation occurs in our HP production media, Day 7, as seen by surface 
expression of CD235, glycophorin A, and CD71, transferrin receptor. This media, while good for 
production and expansion of HPs contains cytokines that block further maturation. Removal of 
the cytokines with addition of plasmanate, and EPO creates a uniform population of 72% 
CD235+CD71+ cells (Figure 3.7). However it took additions to the media and an OP9 stromal 
layer to see minimal enucleation occur (Figure 3.8) and further media changes to get increases in 
hemoglobin content (Figures 3.10 & 3.11), and 35% of cells solely CD235+ in EMM2 (Figure 
3.9).  
 While maturation is important, maturation can occur without hemoglobin switching. This 
is common during development when cells are produced by the AGM. All hemoglobin expression 
seen with our cells in vitro demonstrates that our cells are embryonic and fetal in nature. They 
express HBE, HBZ, HBA, and HBG, but not HBB (Figure 2.11). It is not yet possible to reliably 
generate large quantities of HBB expressing cells from an embryonic source such as hES or 
iPSC233. In 2012, Kobari et al. published that erythroid cells produced from iPSC were capable of 
hemoglobin switching when put into NSG mice182. While no one has been able to replicate 
Kobari’s results, however, the logic behind the experiment was valid. The bone marrow niche is 
extremely complex, consisting of many cell types from multiple cell lineages. To replicate that in 
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a dish without co-culturing is very difficult. To show that iPSC derived erythroid lineage cells are 
capable of switching would validate iPSC disease modeling. Therefore, putting them into an in 
vivo environment that can support them through switching and maturation is a logical idea. 
Preliminary experiments also suggested that it was possible, as I see increased accumulation of 
RBCs in the spleen when the erythroid lineage cells were derived from SCD-specific iPSCs 
(Figure 3.13). This result launched many experiments designed to track erythroid lineage cells in 
the mice so that these cells could be isolated from murine cells and analyzed for hemoglobin 
content.  
 The number of human cells in the mouse is small and they are difficult to find either by 
FACS or by luciferase using an IVIS (Figures 3.15-3.19). The macrophage is one of the 
remaining immune cells in NSG mice, and therefore the suspect in the destruction of the human 
cells. Although others have shown that the macrophage is responsible for the destruction of 
human erythroid cells in NSG mice and that clodronate can increase human chimerism this result 
could not be replicated287 (Figures 3.21 & 3.23). While titration of clodrosome dosage may 
increase viability in the mice, there are other methods to combat macrophage phagocytosis of 
human cells including preventing the macrophage from identifying the cells as foreign. 
CD47, integrin-associating protein (IAP) is expressed on the surface of both human and 
mouse cells. It is most commonly interacts with thrombospondin to control angiogenesis and 
inflammation or with integrin α4β3 to control cell adhesion and migration. When it interacts with 
signal-regulatory protein-α (SIRPα) on macrophages it allows macrophages to recognize cells as 
“self” or “foreign”, with foreign cells being phagocytized. Expression of murine CD47 on human 
cells can prevent phagocytosis by changing the “eat me signal” to a “self” signal288. Others have 
adapted mice to express human CD47 as another method for preventing destruction of human 
cells in mice288,289. As our cells are easily transduced with lentivirus, perhaps a pHAGE 
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expression plasmid that contains murine CD47, can be infected into the human erythroid lineage 
cells and hinder their phagocytosis. 
While this model is currently incomplete, much of the groundwork for the in vivo 
imaging and assays, as well as erythroid maturation experiments have been done. Cell 
morphology, Wright-Giemsa staining and FACS markers CD235 and CD71 can be used to 
determine the maturation state of iPSC-derived erythroid lineage cells. Hemoglobin switching, 
which ultimately will be determined by mass spectroscopy analysis of globin proteins,, could 
occur in the NSG mice. Conditions for sorting human cells from murine peripheral blood and 
spleen homogenates have been determined (data not shown), which will allow for a pure 
population of human cells to analyzed after maturing and switching in vivo. Even if hemoglobin 
switching never occurs in the mice, this model is important for determining the in vivo 
maturation, lifespan and splenic transport of iPSC-derived human cells. 
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CHAPTER 4: 
CHARACTERIZATION OF HbF LEVELS IN SICKLE CELL DISEASE-SPECIFIC 
iPSC-DERIVED ERYTHROID LINEAGE CELLS 
 
Introduction 
Sickle cell disease: a brief description of pathophysiology 
SCD comprises a group of disorders caused by the homozygosity or compound heterozygosity for 
the sickle hemoglobin (HbS; α2βS2) gene. This study focuses on the characterization of erythroid 
lineage cells derived from induced pluripotent stem cells (iPSC) from individuals who have sickle 
cell anemia. Sickle cell anemia is defined as homozygosity for β-globin gene (HBB) codon 6 
GAG>GTG or glu6val mutation. Sickling diseases are prevalent in sub-Saharan Africa, Middle 
East, and the Indian subcontinent. Annually, 280,000 infants with sickle cell disease are born 
world-wide290. HbA, (α2β2), is the normal adult hemoglobin. Eight percent of African Americans 
are carriers of the HbS mutation, and 1 in 600 newborns have sickle cell anemia. Nearly 100,000 
sickle cell disease patients reside in the US. The clinical course of this disease is highly variable 
and affects many organs79. Upon deoxygenation, mutant β-globin polymerizes and forms a rigid 
structure, which is responsible for the characteristic change in erythroid cell shape, from a normal 
biconcave disc to a deformed sickle cell. This rigid β-globin polymer reduces cell flexibility, 
often resulting in vaso-occulusion and hemolysis. Vaso-occlusion, or the process of blocking 
blood vessels with sickled cells, is a predominant clinical manifestation of the SCD (Figure 4.1). 
Occlusive episodes result in painful attacks often treated with opioid analgesics. Numerous 
episodes can result in ischemic injury and permanent organ damage. Despite the presence of HbS, 
individuals can present with a range in the severity of the disease phenotype. This indicates that  
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Figure 4.1. Diagram of HbS polymers altering red blood cell shape and blocking blood flow 
resulting in a vaso-occlusive episode. http://www.nhlbi.nih.gov/health/health-topics/topics/sca/ 
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deoxyHbS polymerization is necessary, but insufficient alone to account for the marked 
heterogeneity of disease manifestations, which are genetically modulated and environmentally 
affected. Fetal hemoglobin (HbF α2γ2) is predominant in the fetus and in infants, and individuals 
with sickle cell anemia have less severe disease when, HbF levels remain high as adults 72,74,83. It 
is now understood that high amounts of HbF lower the concentration of HbS within a cell and 
also inhibits deoxyHbS polymerization74. 
 
Hemoglobin gene expression shifts during development from fetus to adult 
Hemoglobin is a hetrotetramer made from two dimers, each a heterodimer containing one alpha-
type globin and one beta-type globin. Alpha-type globins consist of alpha (α, HBA2, HBA1) and 
zeta (ζ, HBZ) types, with the later expressed solely embryonically. The beta-type globins are 
much more numerous and have specific temporal expression patterns related to development. 
They consist of epsilon (ε, HBE) in the embryo, gamma (Gγ, Aγ HBG2, HBG1) in the fetus, with 
delta (δ, HBD) and beta (β, HBB) in the adult. In the developing embryo and the fetus, the 
majority of heterotetrameric consist of embryonic and fetal hemoglobin forms ζ2ε2 (Gower1), ζ2γ2 
(Portland1), and α2γ2 (HbF), with small amounts of α2ε2 (Gower2). In adults this ratio is reversed, 
with 97% HbA, α2β2, and only trace amounts of α2δ2 (2%) and α2γ2 (<1%) (Figure 4.2). It is not 
uncommon to see this ratio of hemoglobin expression altered in SCD patients, with HbF levels 
reported as high as 30% in adults. 
Hemoglobin haplotype is associated with SCD severity and outcome 
The persistence of HbF into adulthood has been extensively studied for its ameliorative effects on 
HbS polymerization, and has allowed for classification of patients based on genetic markers in 
and around the HBB gene cluster. Restriction site analysis has identified five distinct haplotypes  
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Figure 4.2. Tetrameric forms of hemoglobin present during embryonic, fetal, and adult 
stages of life. The predominant embryonic tetramers made of α, ζ paired with ε are Gower I and 
Gower II. Fetal tetramers are identified as Hb Portland and HbF with HbF the most abundant 
form in fetal development and present in small amounts in adults. The adult the tetrameric 
hemoglobin is HbA1, the most prevalent form, with minor amount of HbA2 formed from the α- 
and δ-globin proteins. Percentages indicate amounts typically present in adults. Modeled after 
http://themedicalbiochemistrypage.org. 
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linked to the sickle cell mutation: Senegal, Cameroon, Benin, Bantu (Central African Republic), 
and Arab-Indian84,85. A patient’s haplotype has been associated with disease severity and 
outcome86. Individuals with the Bantu haplotype have been linked to a severe disease outcome 
due to high incidence of organ damage. Intermediate disease severity is typical with Benin 
haplotypes while the Senegal and Arab-Indian haplotypes have milder symptoms86,87. A mutation 
at -158 position in HBG2 is related to higher HbF levels seen in the Senegalese and Arab-Indian 
haplotypes87. As HbF levels within each haplotype varies, it implies that factors other than 
elements linked to the HBB gene cluster affect HbF concentration.  
 
Quantitative trait loci affect HbF expression in adulthood 
Hereditary persistence of fetal hemoglobin was originally believed to be solely due to deletions in 
the HBB gene cluster  or point mutations in promoters of the γ-globin genes. It is now understood 
that persistence of HbF into adulthood is inherited as a combination of quantitative genetic traits 
that are found throughout the genome. Studies performed on twins by Swee Lay Thein’s group at 
Kings College London School of Medicine, demonstrated that quantitative genetic factors are 
responsible for 89% of HbF level variation89. These genetic factors are commonly known as 
quantitative trait loci (QTLs). QTLs are genetic loci that are associated with a quantifiable 
difference in HbF. The first QTL identified is a single nucleotide polymorphism at the -158 
position of HBG2, found in 1985 by sequencing of the HBG genes291. The C-T polymorphism 
creates an Xmn1 restriction site hence it is sometimes termed the Xmn1-HBG2 locus, and acts in 
cis. Other QTLs act in trans. Genome-wide linkage analysis in an extended Asian-Indian family 
identified a region on chromosome 6q23-q24292,293 linked to higher percentage of HbF expressing 
cells. This region is now known as the HBS1L-MYB intergenic region (HMIP), for the two genes 
it lies between and accounts for 19% of the variation seen in HbF levels of Northern Europeans93. 
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Furthermore, the advent of genome-wide association studies has led to the identification of SNPs 
in chromosome 2p16 through two separate studies94,294. These SNPs in intron 2 of the oncogene 
BCL11A are responsible for 15.1% of the HbF levels in Northern Europeans94. These three 
common QTLs only explain 44% of the variation in HbF expression levels in adults, suggesting 
that there are still unknown QTLs to be accounted for293,295. 
 
Hydroxyurea is an inducer of HbF and the only FDA approved treatment for SCD 
Hydroxyurea (HU) is a ribonucleotide reductase inhibitor originally utilized as chemotherapy 
agent with potent effects on rapidly dividing cells in the bone marrow. It was approved for use as 
a treatment for SCD in February 1998 to reduce the frequency of pain crises and the need for 
blood transfusions in adult patients with recurrent moderate-to-severe painful crises (generally at 
least three during the preceding 12 months)78,296,297. While the efficacy of HU in the treatment of 
SCD is attributed to its ability to boost the levels of HbF, limited work on the genetic 
determinants of the HbF response to HU has been published298. Since HU’s cytotoxic effect is 
most potent in rapidly dividing late erythroid precursors, their removal through stimulated 
apoptosis increases recruitment of early erythroid precursors that can produce HbF. Others have 
suggested that HU acts directly on late precursors to stimulate HbF expression. Alternatively, it 
may interrupt the transcription factors that selectively bind to promoter or enhancer regions 
around the globin genes, thereby altering the ratio of HbA to HbF299.  HU might also have other 
mechanisms of action that account for its utility in SCD. 
 Patient response to HU treatment is highly variable with ten to twenty percent of patients 
having no clinically significant response. It has been hypothesized that the reason certain 
individuals do not respond to HU is due to the capacity of the patient’s marrow to sustain the 
myelotoxicity encountered with HU300. Traditional methods for determining how and why certain 
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individuals respond to HU requires erythroid progenitor cells from many patients and the ability 
to study the bone marrow compartment of the same individuals. As this is technically difficult to 
do, iPSCs have the potential to grant researchers an unlimited supply of erythroid progenitors, 
which allows for the characterization of HU response and HbF levels. iPSC-derived erythroid 
cells also allow researchers to put these cells in mice to observe the in vivo role of the bone 
marrow compartment. 
Materials and Methods 
iPSC derivation and culture: iPSC derivation was achieved using the hSTEMCCA lentiviral 
vector as previously described131.  Peripheral blood mononuclear cells (PBMCs) were used as 
source material for iPSC production143. Individual sample collection occurred at Boston Medical 
Center, Boston, MA or at King Saud University, Riyadh, Saudi Arabia Samples were centrifuged 
at 37°C for 25 minutes at 1800 rcf and the resulting buffy coat was collected in a 15ml Falcon 
tube. Cells were resuspended in 2 ml of expansion medium, consisting of QBSF-60 (Quality 
Biological 160-204-101), 50 ng/ml hSCF (R&D 255-SC-010), 10 ng/ml hIL-3 (R&D 203-IL-
010), 2 U/ml hEPOgen (Amgen), 40 ng/ml hIGF-1 (R&D 291-GI-050), 50 mg/ml Ascorbic Acid 
(Sigma A4403), 100 mg/ml Primocin (Invivogen ant-pm-2) and 1 µM Dexamethasone (Sigma 
D4902).  After 8-9 days, polybrene was added to the media (5 mg/ml) and the hSTEMCCA 
lentivirus was added to the culture at an MOI ranging from 1 to 10.  After 24 hours, the 
inoculated culture was spun at 2250 g for 90 minutes and the polybrene media was discarded.  
The cells were then plated onto irradiated mouse embryonic fibroblasts (iMEFs) and cultured for 
roughly 15 days in “iPSC media” that includes DMEM F12 (Invitrogen 11330057) 10 ng/ml 
bFGF (R&D 233-FB-025) 1 ng/ml rho kinase inhibitor (Cayman Chemical 10005583) 20% 
knock-out replacement serum (KOSR) (Invitrogen 10828028) and 100 mg/ml Primocin.  Clones 
were then picked and expanded for long-term culture.  Hematopoietic progenitors were generated 
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from iPSCs using our previously published protocol278. Cells were kept in D7 media unless 
otherwise noted, 74% IMDM, 24% Hams F12, 1% B27 supplement, 0.5% N2-supplement, 0.5% 
BSA, 50ng/ml hVEGF, 100ng/ml bFGF, 100ng/ml hSCF, 25ng/ml hFlt3 Ligand, 50ng/ml hTPO 
(Genentech G140BT), 10ng/ml IL-6 (R&D 206-IL-010), 0.5U/ml hEPOgen (Amgen) and 0.2 
mM 6-formylindolo[3,2-b]carbazole (FICZ) (Santa Cruz SC300019). Mitomyocin-C treated OP9 
stromal layer was plated on gelatin coated well in DMEM, 10% FBS, 2mM L-Glutamine 
(Invitrogen 25030081), and 100 mg/ml Primocin. 
 
Analysis of clinical records: De-identified and anonymized medical records were examined to 
extract desired information regarding HU usage, HbF levels, and disease pathophysiology. 
Statistical analysis and multidimensional plots comparing the above parameters were done. 
 
Hydroxyurea treatment of iPSC-derived erythroid cells: A final concentration 0.5 µM of HU 
(Sigma H8627-1G), unless otherwise noted, was added to day 7 media. Cells were pelleted, 
washed and resuspended in day 7 media with and without HU. Cells were grown for 3-10 days 
with media additions every other day. The final concentration of HU was maintained throughout 
additions. 
 
Quantitative RT-PCR: RNA was extracted using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions and DNase treated using the DNA-free kit (Ambion AM1906).  
Reverse transcription into cDNA was performed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems 4368814).  Quantitative (real time) PCR amplification of 
cDNA was performed using Taqman probes for HBE (Hs00362216_m1) HBA 
 
 
  
109 
(Hs00361191_g1), HBB (Hs00758889_s1), HBG (Hs01629437_s1) on the Applied Biosystems 
StepOne machine.  Relative gene expression was normalized to B-actin (Hs99999903_m1).  
 
Intracellular flow cytometry: Roughly 10^5 cells, Fetalrol (Trillium Diagnostics, LLC FH101) or 
peripheral blood were collected, spun, and fixed in 0.05% glutaraldehyde (Sigma G5882)-
0.1%BSA-PBS for 10 minutes. Cells were pelleted and washed three times with 0.1%BSA-PBS. 
Cells were permeabilized in 0.1% Triton (Life Technologies HFH10)-0.05%BSA-PBS for 3 
minutes, 0.1%BSA-PBS added, and then cells were pelleted. Cells were re-suspended 0.1%BSA-
PBS for staining. Samples were incubated for 30 min at ambient temperature with human 
antibodies including CD235-PE (BD 555570), and CD71-APC (BD 341028) or 15 minutes with 
HbF-FITC (Life Technologies MHFH01), washed and spun at 3300 rpm for 7 minutes, and re-
suspended in 0.5% BSA in PBS.  Samples were run on a BD FACScalibur using Cellquest Pro 
software and analyzed with FloJo 8.7.   
Results 
Analysis of clinical HbF readings demonstrated variation in HbF levels amongst individuals 
Under an approved of Boston University School of Medicine IRB protocol for the collection of 
patient material for the creation of iPSC lines, consenting patients were  
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Table 4.1. BMC patient enrollment and iPSC generation. Information regarding ability to 
reprogram each patient sample displayed as year_month_day. Numbers of clones generated and 
how many vials were frozen of each clone is included. Grey boxes indicate an inability to 
generate iPSCs with that sample. Pluripotency staining for TRA1-81 was used for quality control. 
Production of iPSCs and staining was performed by S. Rozelle and A. Sommer. 
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Table 4.2. Saudi Arabian patient enrollment and iPSC generation. Information regarding 
ability to reprogram each patient sample displayed as year_month_day. Numbers of clones 
generated and how many vials were frozen of each clone is included. Grey boxes indicate an 
inability to generate iPSCs with that sample. Pluripotency staining for TRA1-81 was used as 
quality control for generated iPSC. Production of iPSCs and staining was performed by S. 
Rozelle and A. Sommer. 
 
 
 
recommended to be part of the study through their clinician.  Patient selection was voluntary and 
random at Boston Medical Center, Boston, MA and at King Saud University, Riyadh, Saudi 
Arabia. Not all samples from patients enrolled in the study were able to generate iPSCs (Tables 
4.1 & 4.2). Due to the fact that this is not a linear study, clinical information was gathered 
retroactively and therefore HbF levels, listed at a percentage of the total hemoglobin are limited 
to readings obtained in the course of regular clinical care (Table 4.3, Figure 4.3A). Despite 
incomplete data the clinical information demonstrates that HbF levels vary in individuals over  
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Table 4.3. HbF levels in Saudi Arabian patients as a factor of age. HbF% of the total 
hemoglobin content in the cells is noted for a range of ages. Lowest and average HbF% levels 
were calculated from readings taken after 4 and 7 years of age respectively.   
 
 
 
 
 
 
Figure 4.3. HbF levels plotted according to time with and without HU treatment. A) SA82 
HbF% graphed in respect to age in years.  B) US24 HbF% graphed in respect to time of HU 
treatment. 
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time irrespective of HU prescription. This could be a result of episodic blood transfusion or 
intermittent use of HU, information difficult to ascertain from available records. 
 
iPSC-derived erythroid lineage cells respond to HU treatment 
To determine if variations in HbF levels resulted from the differential ability of erythrocytes to 
respond to HU, I compared the response of patient-specific iPSC-derived erythroid cells to 
varying dosages of HU. To verify this response I planned to quantify changes in clinical HbF 
mRNA expression in response to HU treatment and determine if these changes correlated with 
changes induced in response to HU in erythroid lineage cells generated from patient-specific 
iPSCs.  
Initial experiments were performed to verify the correct dosage and duration of treatment 
of iPSC-derived hematopoietic progenitor cells (HPs) based on information from previously 
published experiments using K562 cells. Initially I tested various dosages of HU for 5 days and 
saw a robust response in HBG mRNA levels when cells were treated with 0.5 µM HU (Figure 
4.4A). After determining the optimal concentration of HU, I conducted a time course and 
concluded that 10 days resulted in a greater than 2-fold increase in HBG expression (Figure 
4.4B). I compared the increase in HBG between control and SCD-specific derived HPs. I saw a 
difference in HBG expression following treatment with 0.5 µM HU for 10 days. When changes in 
HBG expression were quantified in SCD-specific cells, I found that the relative response to HU 
treatment was distinct for each cell line.  US2.1 had an over 3-fold increase in HBG expression 
compared to SA82.1, whose HBG expression increased 1.3-fold (Figure 4.4C). The level of HBG 
expression in untreated populations also varied significantly between cells lines, with SA82.1 
having a starting amount of HBG expression 4 times higher than US2.1. This led me to question  
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Figure 4.4. HBG levels increase following hydroxyurea treatment in erythroid lineage cells. 
A) RT-PCR for HBG, HBA, and HBB in wildtype cells treated with varying concentrations of 
HU for 5 days, n=1. Expression is normalized to β-actin. B) RT-PCR for HBG, HBA, and HBB 
in wildtype cells treated for 5 or 10 days with 0.5 µM HU, n = 3. Expression is normalized to β-
actin. *P < .05, **P < .005.  C) RT-PCR for HBG, HBA, and HBB in either SCD-specific US2.1 
or SA82.1 cells treated with 0.5 µM HU for 10 days, n=1. Expression is normalized to β-actin.   
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whether baseline HBG expression, as well as the difference in response to HU, was reflective of 
what happened in the patients. 
Determination of HU response in patients was complex due to variables in HU dosage and 
clinical management of the disease.  
To test the hypothesis that patient-specific iPSC-derived erythroid lineage cells are capable of 
recapitulating an in vivo differential HU response, I first needed to determine how observe how 
HU usage affected HbF levels in the patient (Table 4.4, Figure 4.3B). Patient treatment and 
response information was obtained from medical records. Initial inspection revealed highly 
variability among patients in dosage and timing of HU treatments, transfusion frequency, crisis 
history, age, gender and ethnicity, all of which could significantly affect the observed increases in 
HbF protein levels. This nullifies utilizing a simple percentage increase in HbF following 
initiation of HU as a way to determine responsiveness. To account for some of the variables in 
treatment, I decided to compare HbF% (percentage HbF of total hemoglobin) and HU dosage 
(mg) with respect to time. Data surrounding transfusions and crises was noted in an effort to 
reduce the number of variables (Figure 4.5B). Mean corpuscular volume (MCV) values of the 
patient’s RBCs was used as a surrogate to confirm compliance of HU use, as MCV should 
increase above baseline while taking HU301. Each individual had a unique profile based on his or 
her clinical history, which we used to categorize each as a responder versus a poor responder to 
HU (Figure 4.5B). Individuals whom showed greater than a 5% increase in HbF levels with a 
corresponding increase above threshold in MCV were considered responders. Weak responders 
had variable increases and decreases in HbF levels with MCV increases above threshold. Those 
with no visible increase in HbF levels were considered non-responders. While the plots were 
visually informative as to HbF levels, there was additional important data to consider. Clinical  
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Table 4.4. HbF levels in BMC patients while taking hydroxyurea overtime. HbF% at the date 
of collection was obtained from an identical peripheral blood sample as the one for iPSC 
generation. If known, the initial prescription date or earliest BMC prescription date for HU is 
noted. HbF% of total hemoglobin in the cells is listed for time points before and after initiation of 
HU treatment. 
 
 
notes for potential weak/non-responders revealed that many had been explicitly taken off of HU 
treatment (2 of 3 patients), while another was noted as noncompliant with regularly taking their 
medication. Once these individuals were excluded from the analysis, only robust responders 
remained. Having eliminated all potential for a comparison between in vivo clinical treatments 
and in vitro cell-based experiments, I focused the remainder of my research on identifying iPSC 
lines that represent the potential variety of HbF levels and haplotypes. This resulted in the use of 
six iPSC lines, three control and three SCD-specific lines. The SCD-specific lines consisted of 
one African-American (US2.1), one Arab-Indian (SA108.1), and one Benin haplotype (SA82.1) 
with average HbF levels ranging from 6.5%-29.9% (Table 4.5). While there are many SCD-
specific iPSC lines to study, characterization of HU response did not reveal any weak or non- 
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Figure 4.5 Analysis of HbF levels in respect to HU dosage and time. A) Diagram illustrating 
the goal of analyzing HbF% and HU dosage as a product of time.  B) Plots of three individuals 
US4, 24, and 37 in which HbF% (red H), MCV (teal M), transfusions (blue T), and HU dosage 
(⊗) are plotted according to age of the patient in years. MCV is plotted as MCV/10 against a 
normal value of 90 fL (black line). HU is plotted as dose/100 mg in reference to the y-axis. 
 
 
 
 
 
 
 
 
Table 4.5. Cell lines used for analysis of HbF have various baseline HbF levels and 
phenotypes. 
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responders. Therefore, the focus of this project changed to recapitulating the in vivo variation in 
HbF levels in my in vitro system.  
 
HBG and HBA globin gene expression increased in culture over time 
To further understand why there are differences seen in HBG expression in our cultures, I 
performed a time course to test if culture maturation played a role in HBG expression. Cells were 
analyzed by RT-PCR on Day 15, 17 and 24, in which Day 0 is defined as the first day of the HP 
differentiation protocol302. On day 15 cells are isolated from the adherent layer from which they 
originated. I choose day 17 and 24 for the amount of time the cells were absent from the feeder 
layer, under the assumption that the change in culture environment affects the maturation 
capabilities of the cells. Both BU1 and SA82 cell lines showed trend of HBG and HBA expression 
increasing over time (Figure 4.6). This is seen to a smaller lesser extent in SA108.1 as significant 
variability between experimental replications of SA108 masked the emergence of any consistent 
trends. Neither HBB nor HBE showed any significant changes in expression throughout the three 
time points. 
Fetal hemoglobin protein levels showed variation between cell lines and decreased over time 
While gene expression can be indicative of protein expression, it is not always correlative. In 
order to explore the protein levels of HbF, I adapted a clinical assay designed to detect fetal- 
maternal hemorrhage using flow cytometry. This assay allows the quantitative analysis of HbF at 
the single-cell level, which allows for a comparison of multiple time points and conditions. 
Fetalrol, peripheral blood spiked with various amounts of cord blood, was the positive control for 
the presence of HbF, while peripheral blood alone served as the negative control (Figure 4.7). 
Consistent with mass spectrometry results (Figure 2.11), erythroid lineage cells express high 
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Figure 4.6. Globin expression in erythroid lineage cells over time. RT-PCR for HBE, HBG, 
HBA, and HBB on days 15, 17, and 24 in one wildtype, BU1, and two SCD lines SA82 and 
SA108, n=3. Expression is normalized to β-actin. 
 
 
 
 
 
Figure 4.7. Intracellular FACS analysis of HbF protein expression. A) FACS histograms of 
peripheral blood with increasing amounts of HbF can be detected using an intracellular FACS 
protocol. B) FACS histograms of iPSC-derived erythroid lineage cells stained for HbF. C) 
Titering of HbF-FITC antibody in erythroid lineage cells found 2.5 µL to be optimal for detection 
of low and high HbF expressing cells. 
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amounts of HbF. I also attempted to simultaneously assess changes in HbF and HBB protein 
expression using an antibody recognizing HBB. Unfortunately, since RT-PCR quantification of 
HBB gene expression was consistently below the level of detection (Figure 4.6), I was unable to 
draw any meaningful conclusions.   
Both control and SCD cell lines displayed significant variation of HbF levels between 
cell lines and across time points (Figure 4.8). Wildtype lines BU1, 5, and 6 decrease their HbF 
levels as the cells mature overtime, mimicking definitive development. Unfortunately, this trend 
is also seen in SCD-specific lines, suggesting that the cells are undergoing limited maturation and 
are not switching to HbA expression. Statistical analysis revealed no significant differences in the 
mean HbF levels amongst the lines or when comparing grouped wildtype and SCD lines. Perhaps 
a large sample size will give enough power to observe any subtle changes. By not selecting for 
erythroid specific cells in this assay, the cells that were interrogated for HbF expression were a 
heterogeneous population. There could be a small subset of cells that are maturing and switching 
hemoglobin expression, but are masked by the larger population. It was therefore important to 
interrogate the maturation state simultaneously with HbF expression. 
 
Intracellular FACS assay simultaneously determined maturation and hemoglobin expression  
As maturation (progression towards a terminally differentiated erythrocyte) and hemoglobin 
switching are two separate processes, it is imperative to correlate maturation state with HbF 
levels. To accomplish this I modified the previously mentioned intracellular HbF FACS assay to 
include CD235 and CD71. This allows gating for erythroid specific cells with CD235, and 
subsequent examination CD71 and HbF expression with gates generated with single stains 
(Figure 4.9).  Quantification was done to enable comparisons between the control lines (BU5, 
BU6) and SCD-specific lines (US2.1, SA018.1) for multiple criteria. There is an increase in most  
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Figure 4.8. HbF levels vary amongst cell lines and over time. HbF levels plotted as histograms 
in comparison to isotype for three control lines (BU1, BU5, BU6) and three sickle cell lines 
(US2.1, SA82.1, SA108.1) for days 23, 29, and 36 of the differentiation protocol.  
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criteria: CD235+ gating (58.7% vs. 92.5%) CD235+ only (34.9% vs. 88.8%), CD235+ CD71+ 
(20.8% vs. 27.1%), and CD235+ HbF (15.8% vs. 29.8%), between BU5 and SA108.1 (Figure 
4.10 & 4.11). It is expected that a SCD line that has higher HbF compared to control in vivo, will 
have more HbF in vitro. However, quantitatively the other control line BU6 looks more similar to 
the disease lines, demonstrating that there is heterogeneity even in the in the control lines (Figure 
4.11). This heterogeneity makes seeing a disease specific change difficult. Two populations that 
are HbF+, a low (<102) and a high (>102) are found by dot-plot and histogram analysis. BU6 and 
SA108.1 have a population of cells that are HbFlow and CD71low, the description of cells that are 
maturing (migrating to solely CD235+) and undergoing hemoglobin switching (losing HbF 
expression) (Figure 4.11B & C).  
 
Discussion 
 While the use of hES and iPSCs provides an unlimited supply of erythroid progenitors for study, 
iPSCs allow for the creation of SCD-specific iPSC cells. Generation of iPSCs from mononuclear 
cells collected during a routine peripheral blood draws, has enabled us to create SCD-specific 
iPSCs from patients around the world. A diverse library of iPSCs produces patient specific and 
genetically defined erythroid cells and facilitates our ability to repeatedly examine differences 
among patients. 
 A patient’s ability to respond to HU cannot be anticipated, nor is fully understood. 
Initially, the SCD-specific iPSC library was to be utilized to recapitulate a patient’s 
responsiveness to HU, and ultimately for drug screening of potential therapeutics.  HBG 
expression increased following in vitro treatment of erythroid lineage cells with HU. This effect 
was seen in one control and two sickle cell lines (Figure 4.4). It was observed that the SCD lines  
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Figure 4.9. 3-color intracellular FACS for HbF, CD235 and CD71 in day 30 erythroid 
lineage cells. A) Representative FACS dot-plots of triple stained cells B) Representative FACS 
dot-plots of cells gated for CD235 and then interrogated for CD71 and HbF. C) Representative 
FACS dot plots for CD235+ cells interrogated solely for HbF expression as displayed in 
histograms. 
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Figure 4.10. Comparison of day 30 control and SCD-specific erythroid lineage cells for 
HbF, CD235 and CD71 expression. A) Representative FACS dot-plots of triple stained cells 
subsequent gating for CD235+ cells of two control lines (BU5, BU6) and two SCD-specific lines 
(US2.1, SA108.1) B) Representative FACS dot-plots of CD235+ cells interrogated for CD71 and 
HbF expression. C) Representative FACS histograms of CD235+ cells interrogated solely for 
HbF expression. 
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Figure 4.11. Quantification of control and SCD-specific erythroid lineage cells for CD235, 
HbF and CD71 expression in 3-color intracellular FACS assay. A) Representative FACS dot-
plots of triple stained cells gated for CD235+ cells, bar graph of the percentage of CD235+ cells. 
B) Representative FACS dot-plots of CD235+ interrogated for CD71 and HbF expression, bar 
graph of the percentage of cells that are CD235+ only, CD235+ CD71+, CD235+ HbF+, or 
CD235+ CD71+ HbF+. C) Representative FACS histograms of CD235+ cells interrogated solely 
for HbF expression, bar graph of the percentage of cells CD235+ HbF+ by histogram. All data 
represents n=3, except US2.1 n=2. *P<.05, **P<.005. 
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had differential responses to HU in vitro, suggesting that I could recapitulate differences seen in 
the patient. 
As elusive as the reasons behind a patient’s response to HU are the methods to 
characterize strong or weak responders. In an ideal situation, HbF levels of individuals taking 
similar doses of HU could be compared over time, and a percentage increase in HbF levels could 
be used to differentiate strong from weak responders. As we were not selective in enrolling 
patients whom were taking a particular dose of HU, we have very few individuals whom could be 
compared using the above method. This led me to attempt to remove the variability in our clinical 
data by plotting HbF (percentage) and HU prescription (mg) as a product of time with transfusion 
history and MCV values noted. I was able to identify responders, greater than a 5% increase in 
HbF levels with an increase in MCV, weak responders, variable increases in HbF levels with 
increased MCV, and non-responders, no increase in HbF. Unfortunately, the identified weak and 
non-responders were either non-compliant or had been taken off HU (Figure 4.5). While other 
researchers have attempted to classify HU response with other indicators such as in vitro RNA 
expression303,304 or particular haplotypes305,306, no one has derived a predictive model for an 
individual’s ability to respond to HU. 
 Based on the patient information available, I used three SCD iPSC lines to compare to 
three control lines for the remainder of my studies. The SCD lines represent different haplotypes, 
Arab-Indian, and Benin, as well as a range of average HbF levels from 6.5-29.6% (Table 4.5). 
With multiple haplotypes and HbF expression I hoped to visualize differences in HbF expression 
in my in vitro analysis of the lines. 
 Previous results from in Chapters 2 (Figure 8) & 3 (Figure 5A) demonstrated that the HPs 
produced through our differentiation methods are capable of limited maturation in the final 
progenitor media, day 7. I also observed variable HbF expression across iPSC lines by RT-PCR. I 
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therefore analyzed HBG expression in control and SCD-specific lines as a time course in day 7 
media. Both HBG and HBA expression increased over time suggesting the cells ability to alter 
hemoglobin expression as a result of maturation (Figure 4.5).  
Since mRNA expression is not always correlated with protein levels, I sought to 
corroborate our RT-PCR findings with FACS-based protein quantification307. We know from 
mass spectroscopy results (Chapter 2, figure 9) that these cells had high levels of globins typically 
expressed during embryonic development, HBE and HBZ, and during fetal development, HBG 
and HBA. Mass spectrometry is extremely useful for identifying simultaneous expression of 
hemoglobin, but as performed was not quantitative. I adapted an assay for fetal-maternal 
hemorrhage using FACS to quickly and quantitatively assess HbF expression in various cell lines 
over time. This assay allows to me accurately quantify HbF levels in differentiated erythroblast 
cells and observe the reduction in HbF as cells mature into fully differentiated erythrocyte. Since 
the reduction in HbF was so dramatic between day 29 and day 36 (Figure 4.7) I further analyzed 
the maturation state and HbF levels of cells at day 30. 
 Intracellular staining for HbF, while simultaneously staining for maturation markers 
CD235 and CD71, quantitatively describes the maturation state of the cells in respect to HbF 
expression. Interestingly, BU6, a control line and SA108.1 have similar levels of CD235 
expression and HbF expression when analyzed individually. When compared together, the SCD-
specific lines have a higher proportion of CD235+HbF+ cells than the control lines (40.7% vs. 
14.0%). Two populations of HbF expression: high and low, were observed both by scatter-plot 
and histogram analysis of CD235+ cells (Figure 4.8). This suggests that the cells are able to 
mature and may be capable of hemoglobin switching. It is important to note that without FACS 
data for other hemoglobins, switching cannot be confirmed and these results may represent 
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variation in embryonic hemoglobin as well. While these differences are subtle, they do suggest 
that this system is capable of recapitulating in vivo differences seen between individuals. 
 Each iPSC line, control or SCD-disease specific is capable of creating erythroid lineage 
cells that can be used to characterize both maturation state and HbF levels. When comparisons 
were made amongst lines, subtle differences in HbF levels and maturation states were seen. These 
cells, while expressing primarily HbF, can modulate their HbF levels in response to maturation or 
HU treatment. These results further demonstrate that iPSC-derived erythroid lineage cells are 
capable of reflecting the differences seen between individuals. It is interesting to note that most 
clinical differences are observed in cells that express primarily HbA globin, and little has been 
done to study HbF modulation in primitive erythroid cells expressing HbF. My results suggest 
that HbF levels can be modulated in primitive cells, however, I hypothesize that a profound 
difference, similar to that seen in the patients, in HbF levels will be observed between lines in 
cells expressing HbA.  
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CHAPTER 5: 
GENERAL DISCUSSION 
 
Erythropoiesis has been studied extensively in xenopus, zebrafish, rats, chickens, mice, and 
humans. Yet with all we understand about the process of making RBCs, efficiently recapitulating 
this process in vitro continues to elude researchers. The limitation in the production of RBCs has 
hurt the SCD field’s ability to conduct a global study without returning to the patient for fresh 
samples. The use of hES and iPSCs give researchers an unlimited supply of patient material, but 
only iPSCs allow for the creation of SCD-specific iPSC cells. By generating iPSCs from 
mononuclear cells collected during a routine peripheral blood draws; we have been able to create 
SCD-specific iPSCs from around the world. This diverse library of iPSCs allows for the 
production of erythroid cells that mimics the genetic context of the patient and facilitates our 
ability to repeatedly examine differences between patients. Unfortunately, an even more difficult 
process than making patient specific RBCs, is making RBCs that have matured to produce 
enucleated RBCs with expression of HbA233. HbA expressing RBCs are an ideal tool for studying 
novel SCD therapeutics and recapitulating clinical differences observed in the patient. Using 
erythroid progenitors derived from iPSCs generates large numbers of cells can be obtained for 
studies into the steps of maturation and hemoglobin switching as well as exploring new HbF 
inducing drugs.  
 The goals of this project have evolved as we have learned more about the patients and the 
cells we have generated. The first goal was the efficient generation of erythroid lineage cells from 
an iPSC source without the support of co-culturing with feeder cells. Our methodology to 
produce HPs utilizes a two dimensional system in which the oscillation of cytokine signaling 
allows the cells to create their own microenvironment. The oscillation mimics the cytokine 
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gradient seen in early germ layer, tissue, and cell lineage specification. The cells produced are 
very similar to the short-lived MEP in surface marker expression, mRNA expression, and lineage 
specification. While the length of time to produce progenitor cells is shorter than previously 
published results, the limited number cells produced was similar. We then explored a new area of 
hematopoietic research based on recently published literature suggesting that the AhR is involved 
in stem cell and progenitor expansion160. 
We discovered that the AhR agonist FICZ has a physiological and functional role in 
normal hematopoietic development, and that modulation of the AhR in bipotential hematopoietic 
progenitors can direct cell fate to either the erythroid or megakaryocyte lineage. Incorporation of 
FICZ in our directed differentiation protocol dramatically increases the number of HPs produced.  
This is very important for multiple reasons, one the revelation that AhR plays a role in the growth 
and differentiation of two blood cell types; and two, that the expansion of HPs resulted in 
tremendous numbers of cells for the further study of both the megakaryocyte and erythroid 
lineages. We believe that the observed logarithmic expansion of cells is due to decreased cell 
death and is consistent with previous studies which suggest that the AhR can control apoptosis211–
213. Our data suggests that FICZ, which is produced naturally as a tryptophan metabolite, could be 
playing a role in the regulation of hematopoiesis in vivo, possibly in concert with additional 
endogenous AhR ligands.  
In addition to allowing for the exponential expansion of HPs, our results indicate that 
AhR modulation is involved in the further specification of both the erythroid and Mk lineages. 
We found that increased AhR signaling supports the differentiation of erythroblasts and 
conversely, antagonism leads to Mk specification. Although EPO and thrombopoietin are the 
major drivers in RBC and platelet development, our results suggest that AhR may play a 
cytokine-independent role in the development and specification of these lineages.   
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With the efficient generation of HPs that could be directed to the erythroid lineage, my 
subsequent goal became the generation of an in vitro system in which to produce enucleated 
RBCs. Erythroid cell maturation and hemoglobin switching are two separate processes that do not 
rely on each other. Mature cells can produce HbA or persist in HbF expression, however 
primitive cells rarely produce HbA. I set out to characterize the ability of iPSCs-derived erythroid 
lineage cells to mature and express HbA. Erythroid maturation occurs most reliably on stromal 
cell layers such as murine fetal liver or human bone marrow stroma (OP9). Since co-culturing 
creates opportunities for contamination of the produced cells, I set out to demonstrate that our 
cells are capable of maturation, and then to do so in a chemically defined manner. Limited 
maturation was observed in our HP production media, Day 7, as seen by surface expression of 
CD235 and CD71. This media, while good for production and expansion of HPs, contains 
cytokines that block further differentiation and maturation. Ultimately the removal of progenitor 
producing cytokines with addition of plasmanate, EPO, and transferrin creates a uniform 
population of CD235+CD71+ cells. Alternatively cells solely CD235+ can be produced in 
erythroid maturation media 2. This same media was responsible for an increased production of 
hemoglobin, which is required for maturation. This demonstrates that the cells are capable of 
maturation. 
Very limited, if any enucleation was seen in cells that were capable of maturation. This 
may result from the lack of supporting macrophages or ideal culturing conditions. Many believe 
that signaling from the macrophage is responsible for the final stage of maturation, the expulsion 
of the nucleus65. It would be interesting to see if there is an increase in enucleation when cells that 
have been in EMM2 are co-cultured with macrophages. Similar to the erythrocyte maturation 
field, only recently has a efficient chemically-based protocol for the production of macrophages 
from iPSC been developed, as all previous methods required co-culture and purifications steps308. 
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These results suggest that soon researchers will be able to produce RBCs and macrophages from 
the same individual that can be co-cultured for the efficient production of mature, enucleated 
RBCs. 
 Cells capable of maturation may not undergo hemoglobin switching and express HbA. 
This is seen in RBCs produced by the AGM that are capable of maturation, but still express 
embryonic globin. iPSC-derived erythroid lineage cells are embryonic and fetal in nature, as seen 
by RNA and protein expression studies. These cells express HBE, HBZ, HBA, and HBG, but not 
HBB. It is not yet possible to reliably generate large quantities of HBB expressing cells from an 
embryonic source such as hES or iPSC233. As the bone marrow niche in which cells mature and 
undergo hemoglobin switching is extremely complex, consisting of many cell types from multiple 
cell lineages, it suggest that many factors are involved in the production of HbA expressing 
RBCs. Replication of that environment in vitro, without co-culturing is very difficult. To validate 
that iPSC can be used for RBC disease modeling, I utilized an in vivo environment that can 
support them through switching and maturation, the humanized mouse model.  
The humanized mouse model allowed me to inject human erythroid lineage cells into 
sub-lethally irradiated mice and compare them before and after they spend time in a natural 
hematopoietic environment. Early experiments indicated that the cells were capable of homing to 
the bone marrow and maturation, which resulted in increased splenic clearance of the extra RBCs. 
This result prompted the creation of a lentiviral vector to transduce a constitutive luciferase 
expression construct. Cells properly incorporating this sequence into their genome allowed in 
vivo imaging throughout a multi-day time course. While I was able to visualize the cells for the 
first week, subsequent imaging revealed decreasing numbers of cells. At 3 weeks post injection, 
the signal from human cells had decreased below the level of detection using either FACS or 
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organ-level luciferase imaging. I hypothesized that this diminution of human cells was due to the 
mouse immune system clearance. 
The macrophage is one of the remaining immune cells in NSG mice, and therefore the 
suspect in the destruction of the human cells. Although others have shown that macrophage cells 
are responsible for destruction of human erythroid cells in NSG mice and the use of clodronate to 
deplete macrophage populations can increase human chimerism in this model, this result could 
not be replicated287. Future experiments under this aim should investigate further titration of 
clodrosome vesicle dosage to increase animal viability. Alternatively, increasing the number of 
mice in the study would allow for significance despite some premature mortality. I chose to 
continue this line of investigation by directly blocking macrophage identification of human cells. 
CD47 is an integrin-associating protein (IAP) expressed on the surface of both human 
and mouse cells. Upon CD47 binding to signal-regulatory protein-α (SIRPα) on macrophages, 
macrophages identify the presenting cell as “self” or “foreign”, with foreign cells being 
phagocytized. Expression of murine CD47 on human cells can prevent phagocytosis by changing 
the “eat me signal” to a “self” signal288. Others have adapted mice to express human CD47 as 
another method for preventing destruction of human cells in mice288,289. As our cells are easily 
transduced with lentivirus, my future goal is to create a pHAGE expression plasmid that contains 
murine CD47, which can be infected into the human erythroid lineage cells and hinder their 
phagocytosis when injected into mice. 
By optimizing mouse in vivo imaging, cellular assays, and erythroid maturation 
procedures I have laid a solid groundwork for establishing an in vivo and in vitro model for RBC 
maturation. Methods to assess cell morphology and surface markers to determine the maturation 
state can be used to compare iPSC-derived erythroid lineage cells. Furthermore, once the cause of 
human cell loss is counteracted, NSG mice should serve as the ideal vessel for studying the 
 
 
  
134 
process of hemoglobin switching, which ultimately can be determined by subsequent mass 
spectrometry. Conditions for the isolation of human cells from murine peripheral blood and 
spleen homogenates by cell sorting have been established. This allows for a pure population of 
human cells to be analyzed after maturing and switching in vivo. Regardless of an iPSC-derived 
human cell’s ability to undergo hemoglobin switching, this model is crucial for testing human 
cells ability to mature, navigate the spleen and survive an in vivo environment, prior to being used 
in a clinical setting. 
With the ability to create erythroid lineage cells I was able to pursue the last goal of this 
project, the comparison of wildtype and SCD-specific iPSC-derived erythroid cells. Since iPSCs 
mimic the genetic context of the patient I hypothesized that not only would I see differences 
between wildtype and SCD-specific cells, but also within SCD lines in regards to HbF expression 
and response to HU.  
 The ability of a patient to respond to HU is unpredictable. With a library of SCD-specific 
iPSC I proposed to study HU responders versus poor responders in the hope of identifying 
differences that would allow for a targeted search for novel therapeutics. My experiments 
demonstrated that HBG expression increased following in vitro treatment of erythroid lineage 
cells with HU. This effect was observed in both control and sickle cell lines. SCD lines showed a 
range of differential responses to HU in vitro, suggesting that the ability to recapitulate 
differences seen in the patient was feasible. Unfortunately, due to irregular clinical treatment and 
HbF readings, patient responses to HU could not be reliably determined. 
In an ideal situation, HbF levels of individuals taking similar doses of HU could be 
compared over time, and a percentage increase in HbF levels could be used to differentiate strong 
from weak responders. In the creation of our library we were not critical in enrolling patients 
prescribed a common dose of HU, nor were we able to define the frequency with which their HbF 
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levels were measured, two facets which led to confounding results. In an attempt to extract 
cryptic trends in our clinical data we charted HbF (percentage) and HU prescription (mg) as a 
product of time with transfusion history and MCV values noted. This method identifies HU 
responders as those with greater than a 5% increase in HbF levels upon HU prescription with a 
corresponding increase in MCV. Weak responders had variable increases and decreases in HbF 
levels less than 5% with increased MCV, and non-responders showed no significant change in 
HbF. Regrettably, all patients identified as weak or non-responsive were flagged as either non-
compliant or had been taken off HU, leaving nothing to compare with the HU responders. While 
other researchers have attempted to classify HU response with other indicators such as in vitro 
RNA expression303 or particular haplotypes305,306, no one has derived a predictive model for an 
individual’s ability to respond to HU. I believe that utilization of a SCD-specific iPSC library is a 
valuable tool to study HU response, however, establishment of such a model system first requires 
validation with individuals that have a thorough history of HbF levels, minimal transfusions and 
consistent HU prescription.  
 Using the patient information available, I decided to use three SCD iPSC lines to 
compare to three control lines for the remainder of my studies. The SCD lines represent distinct 
haplotypes Arab-Indian, and Benin. These SCD lines all show an increase in HbF expression 
(6.5-29.6%) compared with the <0.5% HbF seen in control lines. With multiple haplotypes and 
HbF expression I hoped to visualize differences in HbF expression in my in vitro analysis of the 
lines. 
 Previous results demonstrated that HPs are capable of limited maturation in the final 
progenitor media, day 7. I conducted a time course to observe mRNA expression changes in day 
7 media that revealed both HBG and HBA expression increased over time. This suggested that the 
cells are capable of altering hemoglobin expression as a result of maturation. I sought to 
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corroborate my RT-PCR findings with FACS-based protein quantification307. Mass spectrometric 
results revealed that the erythroid lineage cells had high levels HBE, HBZ, HBG and HBA. While 
mass spectrometry is extremely useful for identifying simultaneous expression of hemoglobin, it 
is typically not quantitative. I adapted a clinical fetal-maternal hemorrhage FACS assay to 
quickly and quantitatively assess HbF levels in various iPSC derived erythroid cells. With this 
assay I was able to quantify HbF levels in differentiated erythroblast cells and observe the 
changes in HbF levels as cells mature. I observed a dramatic reduction in HbF between day 29 
and day 36, prompting me to analyze the maturation state and HbF levels of cells at day 30. To 
analyze maturation and HbF levels simultaneously required further adaptation of the intracellular 
HbF FACS assay. Analysis of multiple control and SCD-specific lines revealed interesting trends. 
BU6, a control line and SA108.1 had similar expression levels of CD235 and HbF. The SCD-
specific lines had a higher proportion of CD235+HbF+ cells than the control lines (40.7% vs. 
14.0%), which may reflect the higher levels of HbF seen in the patients compared to control. Two 
populations of HbF expression: high and low, were observed both by scatter-plot and histogram 
analysis of CD235+ cells. This suggested that day 30 cells were currently in the process of 
maturation and hemoglobin switching. Despite the small number of lines used for these 
experiments, we were able to identify trends in our in vitro iPSC based system that recapitulated 
in vivo observations. 
 Collectively, these results demonstrate that each iPSC line, control or SCD-disease 
specific, is capable of creating erythroid lineage cells that can be used to characterize in vitro and 
in vivo maturation states as well as hemoglobin expression. Evaluation of HbF in each line 
revealed subtle differences in HbF levels and maturation states while still demonstrating the 
ability of the cells to modulate their HbF levels in response to maturation or HU treatment. These 
results validate my original hypothesis that iPSC-derived erythroid lineage cells are capable of 
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reflecting a similar range of differences observed in individuals. However, it is important to 
acknowledge that the observed clinical differences are seen in mature erythroid cells that express 
HbA globin, and little has been done to study HbF modulation in primitive erythroid cells 
expressing HbF. While my results suggest that HbF levels can be modulated in primitive cells, I 
hypothesize the profound differences in HbF levels will be seen once cells expressing HbA are 
produced. 
Since our in vitro differentiation procedure appeared to be producing mature 
erythroblasts without the accompanying hemoglobin switching, we became convinced that we 
were modeling primitive erythropoiesis. Primitive erythropoiesis, which takes place during 
embryonic and fetal development results in RBCs, which are capable of maturation, but will 
express primarily embryonic and HbF. Historically, multiple cells types derived from iPSCs have 
been observed to be fetal in nature, unable to express proteins typical of adult cells. This is 
highlighted by the difficulty of altering erythroid lineage cells to produce HbA, despite repeated 
advances in the production of the cells. Mass spectrometry data showing embryonic and fetal 
hemoglobin expression supports the model of primitive erythropoiesis and is reinforced by FACS 
analysis of the adherent and non-adherent layers. We found that the non-adherent population we 
were collecting had fewer hematopoietic stem cell-like cells than the small population found in 
the adherent layer. This suggested to us that altering an early step to allow for definitive 
erythropoiesis is key (Figure 5.1). An early cell type of interest is the hemogenic endothelium 
from which definitive HSC arise. If we are capable of producing the environment that HSC are 
derived from, we should be able to capture HSC-like cells for expansion and differentiation. Very 
preliminary results from our lab suggest that this is possible with the addition of SB431542, an 
activin and nodal inhibitor, at day 4 of our differentiation protocol. Addition of SB43152 on day 4 
increased the CD34+, and HSC surface marker, cell population from 3 to 21%. These HSC-like 
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cells can be purified from the rest of the adherent layer, re-plated, and allowed to continue 
producing HPs. The HPs that are produced are capable of expressing HBB under maturation 
conditions, as seen by RT-PCR. The ability to harness these HSC-like cells for the support of a 
definitive erythropoietic environment will allow for optimal comparisons of wildtype and SCD-
specific erythroid cells. 
In addition to answering basic biological questions concerning hematopoietic and 
erythroid development, our in vitro platform could also be used for the production of  
 
 
 
 
Figure 5.1. Diagram illustrating differences in cells generated from primitive or definitive 
hematopoiesis.   
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blood products in a chemically defined and xenobiotic agent-free differentiation scheme.  As 
blood transfusions are an indispensable cell therapy, and the safety and adequacy of the blood 
supply are of national and international concern, an iPSC-based system could allow for red blood 
cell and platelet transfusion, without problems related to immunogenicity, contamination, or 
supply.  It has been posited that only a few individuals will be needed for iPSC generation to be 
able to create blood products for all HLA matched groups309. Furthermore, the ability to produce 
multiple populations of cells from a single source, coupled with the fact that both platelets and 
mature RBCs contain no nuclear genetic material, decreases safety concerns with the use of 
iPSC-derived cells and paves the way for clinical utility.   
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